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Amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are fatal diseases 
presenting with degeneration and loss of lower motor neurons in the brainstem and spinal cord. 
However, oculomotor and trochlear motor neurons that control eye movement, are resistant 
until late stages of disease. Moreover, individual motor neurons degenerate in a distinct pattern. 
Firstly, the distal synapse between motor neuron and muscle, the neuromuscular junction 
(NMJ), becomes denervated. Subsequently, the neuron degenerates in a retrograde manner, 
until the cell body in the spinal cord is lost later in disease. This highlights the distal axon and 
NMJ as the most vulnerable subcellular compartment of motor neurons. 
We set out to investigate the mechanisms that underlie the resistance of oculomotor neurons, 
as well as the differential vulnerability within motor neurons themselves. We first validated the 
resistance of oculomotor neurons in two mouse models of ALS and SMA in Paper I. Next, we 
performed a large transcriptomic screen of differentially vulnerable motor pools in SMA mice 
throughout disease progression in Paper II. We used laser capture microdissection (LCM) to 
dissect motor neurons from different pools in the brainstem and spinal cord. Here we revealed 
pathways and transcripts that were enriched only in the resistant oculomotor neurons that serve 
to prevent them from going into apoptosis, as well as promote their regeneration. We showed 
that applying one of the oculomotor-enriched transcripts, Gdf15, to vulnerable spinal motor 
neurons derived from stem cells improved their survival. Next, in Paper III we utilised in vitro 
approaches and generated a model of oculomotor resistance in ALS by deriving both spinal 
and oculomotor neurons from mouse embryonic stem cells. Here we found that in vitro 
oculomotor neurons are more resistant to excitotoxic stress and have increased levels of pro-
survival Akt-signaling, which also held up in LCM-dissected post-mortem human spinal and 
oculomotor neurons. 
To investigate the vulnerability of the distal axon, we generated a technique called Axon-Seq 
in Paper IV, that allows transcriptomic profiling of isolated motor axons by culturing motor 
neurons in microfluidic chambers. We subsequently used this technique in Paper V to show 
that human stem cell-derived motor neurons carrying ALS-causative mutations in FUS and 
TDP-43 showed unique transcriptome dysregulation in somas and axons. This implies that 
different pathways of degeneration are at play between subcellular compartments, and provides 
novel targets for therapeutic intervention directed at different compartments of the motor 
neuron. 
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Motor neurons are highly polarised cells that send axons across large distances in the body. 
They can be subdivided in two groups: the upper motor neurons, which project down from the 
cerebral motor cortex into the brainstem and spinal cord, and lower motor neurons, projecting 
outward from the brainstem and spinal cord towards skeletal muscles. At the skeletal muscle, 
a specialised synapse termed the neuromuscular junction (NMJ) is responsible for signal 
transmission from the motor neuron to the contractile myofibre, thereby controlling voluntary 
muscle movement.  
 
In the fatal diseases amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) 
the motor system is selectively affected, with degeneration of lower motor neurons in both 
diseases as well as degeneration of upper motor neurons in ALS. This results in the loss of 
voluntary motor control and ultimately severe muscle wasting and paralysis. Depending on the 
degree of upper motor neuron degeneration in ALS, additional symptoms can include spasticity 
and hyperreflexia. The cause of death is respiratory failure due to paralysis of the intercostal 
and diaphragm muscles, both responsible for breathing. 
 
1.1 AMYOTROPHIC LATERAL SCLEROSIS 
 
ALS is an adult-onset disease, typically starting between 30 and 60 years of age, with a fast 
progression. Initial symptoms are heterogeneous, largely depending on the level of upper motor 
neuron degeneration, but classically involve muscle fasciculations and muscle weakness 
starting at the distal extremities. Around 20% of patients first present with bulbar (speech and 
swallowing) difficulties (Swinnen and Robberecht, 2014). Approximately 25% of patients 
survive until 5 years after diagnosis, and this decreases to around 10% at 10 years post-
diagnosis (Pupillo et al., 2014).  
 
Currently no cure exists for ALS, and treatment is limited to Riluzole (Rilutek) and, only in the 
US and Japan, Edaravone (Radicava). Both drugs extend lifespan by a few months at most 
(Luo et al., 2018; Miller et al., 2012), and are not effective for all patients. More general 
symptomatic treatments include medication against pseudobulbar affect (uncontrolled 
emotional outbursts), excessive saliva production (to aid with swallowing) and muscle 
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relaxants (to counter fasciculations and spasms). In addition, physiotherapy is often prescribed 
in an attempt to maximise muscle strength and control. 
 
1.1.1 Genetics and disease mechanisms of ALS 
 
The majority of ALS cases appear sporadic (90%, sALS), while the remaining 10% are familial 
(fALS), meaning there is a clear family history of the disease. Mutations in several genes are 
known to cause ALS, the most common being C9orf72, as well as SOD1, TARDBP (TDP-43) 
and FUS (reviewed in Renton et al., 2014 and Taylor et al., 2016). Mutations are present in 
both sALS and fALS cases, and knowledge from fALS inheritance shows that the disease is 
almost always transmitted as a dominant trait with high penetrance (Taylor et al., 2016). 
Disease presentation and progression is not sufficient to pinpoint the underlying mutation, or 
even to distinguish fALS from sALS (Swinnen and Robberecht, 2014). Nonetheless, some 
genetic variants predispose to certain characteristics, for example an early (sometimes juvenile) 
onset with certain FUS mutations (Naumann et al., 2019) and strong initial lower-limb 
involvement and paralysis with certain SOD1 mutations (Cudkowicz et al., 1998). 
 A common neuropathological hallmark of the disease is the presence of 
intracellular inclusions of ubiquitinated TDP-43, the protein product of the TARDBP gene, in 
the vast majority (> 95%) of all ALS cases, regardless of their genetic aetiology (Neumann et 
al., 2006). Approximately 4% of cases are comprised of SOD1- and FUS-ALS, presenting with 
mutations in, and protein aggregates of these two genes (Mackenzie et al., 2007; Vance et al., 
2009). FUS-positive inclusions have also been observed in non-FUS ALS, but what proportion 
of non-FUS ALS cases present with these inclusions is unclear (Deng et al., 2010; Ikenaka et 
al., 2020; Tyzack et al., 2019). 
 
Mutations in Cu-Zn superoxide dismutase (SOD1) were the first ALS-linked variants to be 
discovered in 1993 (Rosen et al., 1993). SOD1 is an important and highly conserved 
antioxidant enzyme, present in all cells. The most widely studied mouse model of ALS is based 
on overexpression of the human SOD1G93A mutation. This model recapitulates the disease well, 
with an adult-onset neurodegeneration and a fast progression of paralysis (Gurney et al., 1994). 
Misfolded SOD1 protein can aggregate and form cytoplasmic inclusions. While such SOD1+ 
inclusions are universally observed in post-mortem tissue of mutant SOD1-related ALS 
patients, the role and presence of SOD1+ inclusions in non-SOD1 fALS and sALS is not 
entirely clear yet. While some studies find virtually no presence of SOD1 misfolding and 
aggregation in sALS (Ayers et al., 2014; Cruz et al., 2017), others do show the presence of 
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misfolded SOD1 in post-mortem tissue from sALS patients (Forsberg et al., 2010; Paré et al., 
2018; Ruegsegger et al., 2015). This discrepancy has been attributed to differences in tissue 
staining protocols (Paré et al., 2018), epitopes that are missed by certain antibodies (Ayers et 
al., 2014) and misidentification of normal staining patterns as aggregation (Cruz et al., 2017). 
Nonetheless, it seems that at least in a small proportion of sALS cases misfolded and possibly 
aggregated SOD1 pathology is present. How commonly it presents and to what extent it 
contributes to disease progression is yet unclear. It is possible that it represents a downstream 
process that only shows in severe cases. 
 Mutant SOD1 also impacts motor neurons in a non-cell-autonomous manner. 
Chimeric mice containing wild-type (non SOD1-overexpressing) motor neurons that were 
surrounded by SOD1-mutant cells still showed pathology and degeneration (Clement et al., 
2003). Later it was shown that targeted removal of mutant SOD1G37R from motor neurons only 
delayed onset and early progression of disease, but did not prevent it (Boillée et al., 2006). 
Conversely, targeted removal of the mutant transgene only from microglia or astrocytes did not 
prevent disease, but slowed progression drastically (Boillée et al., 2006; Yamanaka et al., 
2008). This suggests that mutant protein in motor neurons is the driver of disease onset and 
early progression, while glial cells contribute to later disease progression. Furthermore, 
expression of mutant transgenes solely in motor neurons is sufficient to trigger motor neuron 
loss and an ALS-like phenotype in animals, even though the surrounding cells were not 
genetically compromised (Huang et al., 2012; Jaarsma et al., 2008). Taken together, this paints 
the picture that, at least for SOD1 mutations, carrying the mutant protein in motor neurons is 
sufficient, but not required for disease initiation. Meanwhile glial cells, not required for disease 
initiation, play an important role in progression. 
 
The pathogenic ALS phenotype in SOD1 mice does not strongly rely on changes in the regular 
enzymatic activity of the protein. Rather, a toxic gain-of-function of the misfolded protein is 
thought to cause ALS. Most SOD1 mutants have intrinsically normal antioxidant activity 
(Bruijn et al., 1998; Hayward et al., 2002; Wong et al., 1995), and mutations in patients are for 
the vast majority autosomal dominant, instead of recessive as would be expected in a loss-of-
function paradigm. Genetic removal of SOD1 systemically in mice also does not lead to a 
motor system phenotype, although motor neurons become less effective in their response to 
injury and muscle fibres show aberrant properties (Nagahisa et al., 2016; Reaume et al., 1996). 
Vice versa, overexpression of wild-type SOD1 also does not result in an ALS-like phenotype, 
but it does cause mild NMJ denervation, resembling that normally seen in ageing mice (Epstein 
et al., 1987; Gurney et al., 1994). Interestingly, SOD1 was shown to be exported from cells and 
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released from dead cells in culture, triggering aggregation in other cells in a prion-like way 
(Grad et al., 2014). 
 
In the C9orf72 gene, a large (GGGGCC)n hexanucleotide repeat expansion was identified that 
is currently the most common genetic variant in both fALS and sALS (DeJesus-Hernandez et 
al., 2011; Renton et al., 2011). In healthy people this gene carries around 20 expansions, which 
rises to several hundreds or even thousands of repeats in ALS patients. Interestingly, this repeat 
expansion also underlies frontotemporal dementia (FTD). The function of the C9ORF72 
protein is not entirely clear. While haploinsufficiency of C9ORF72 in in vitro motor neurons 
results in decreased survival under stressed conditions (Shi et al., 2018), full knock-out 
approaches of the homologue gene in mice have not been able to recapitulate a motor 
phenotype. Instead, mice display an immunological phenotype characterised by cytokine 
storm, splenomegaly, lymphocyte infiltration in many tissues and elevated autoantibodies 
(Atanasio et al., 2016; Jiang et al., 2016; Sudria-Lopez et al., 2016). Thus, it is likely that a 
gain-of-function causes the ALS phenotype.  
The hexanucleotide repeat sequence was found to give rise to so-called repeat-
associated non-ATG dependent translation (RAN-translation) (Zu et al., 2010). RNA is 
transcribed directly from the repeat sequence and being translated into long dipeptide repeat 
proteins based on all reading frames in the DNA sequence, sense and anti-sense. These 
dipeptide repeat proteins aggregate and a subset of them, particularly the arginine-containing 
peptides, result in cellular stress (Ash et al., 2013; Mori et al., 2013). In addition, RNA 
transcripts from C9orf72 aggregate in intranuclear RNA-protein inclusions (RNA-foci), which 
also confer stress to the neurons and result in axon outgrowth and branching defects in zebrafish 
(Donnelly et al., 2013; Swinnen et al., 2018). The importance of RNA-induced toxicity is still 
debated, however. Depending on the model system used, RNA-foci appear to be contributing 
strongly to disease (Swinnen et al., 2018) or rather the opposite, with the dipeptide repeat 
proteins being the main culprit (Mizielinska et al., 2014; Moens et al., 2018). Several groups 
reported that nucleocytoplasmic transport was impaired in drosophila models expressing 
expanded C9orf72 repeats that gave rise to toxic dipeptide proteins (Freibaum et al., 2015; 
Jovičić et al., 2015; Zhang et al., 2015). Still, in what order these events occur and which can 
actively trigger or contribute to neuronal degeneration is debated. TDP-43 pathology was 
detected in C9ORF72-ALS patient tissue, though often not in the same aggregates (Mackenzie 
et al., 2013; Murray et al., 2011). Yet, the link between C9ORF72-induced pathology and TDP-
43 pathology is unclear. It is plausible that dipeptide repeat proteins or RNA-foci could initiate 
aggregation of RNA-binding proteins, such as TDP-43, providing an upstream disease process 
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that culminates in TDP-43 pathology similar to other forms of ALS. Thus far only one report 
directly linked dipeptide repeat proteins to accumulation of TDP-43 pathology in a Drosophila 
model of C9ORF72-ALS (Solomon et al., 2018). It therefore remains to be investigated where 
C9ORF72-ALS converges with other types of ALS. 
 
After the discovery that the vast majority of ALS cases present with TDP-43 positive inclusions 
(Neumann et al., 2006), it was found that mutations in TARDBP also underlie a moderate 
portion of fALS cases (Sreedharan et al., 2008). Soon after, mutations in FUS were also 
identified to cause fALS (Kwiatkowski et al., 2009; Vance et al., 2009), with both FUS and 
TARDBP underlying approximately 4-5% of fALS cases (Lattante et al., 2013). TARDBP and 
FUS both encode RNA-binding proteins with diverse functions. Mutations in both genes 
cluster in the RNA-binding domains, while in FUS many mutations also localise to the nuclear 
localization signal domain. The functional homology between these genes implicates abnormal 
RNA biology as an upstream mechanism in ALS. 
FUS-ALS cases present with cytoplasmic FUS+ inclusions (King et al., 2015; 
Vance et al., 2009). Inclusions of FUS have also been detected in human sALS post-mortem 
tissue, sometimes co-localising with TDP-43 (Deng et al., 2010; Ikenaka et al., 2020; Tyzack 
et al., 2019). It is not clear how widespread FUS aggregates are in sALS and non-FUS fALS, 
as many studies have not actively looked for these inclusions. Interestingly, the otherwise so 
ubiquitous TDP-43+ inclusions are absent in FUS-linked ALS, potentially placing TDP-43 
further upstream to FUS. Both TDP-43 and FUS positive inclusions have been shown to co-
localize with stress granules. These are a pan-cellular stress response comprised of membrane-
less aggregates of all components of the translation pre-initiation complex: poly-adenylated 
mRNAs, RNA-binding proteins and ribosomal subunits (reviewed in Aulas and Vande Velde, 
2015). They only appear under cellular stresses, such as osmosis or oxidative stress. Normally 
when the stressor subsides, stress granules dissolve and disappear again shortly after. 
Functionally, they are thought to protect the mRNA from harmful circumstances, as well as 
provide time to decide whether certain mRNAs still need to be translated or should be stored 
or degraded in the face of stress. In the context of ALS, it has been shown that after TDP-43 
co-aggregates with stress granules upon their formation, it can remain aggregated even when 
the stress granules are dissolving again, possibly leading to more toxic types of aggregates 
(Becker et al., 2017; Gasset-Rosa et al., 2019). 
 
Since both mutant FUS and TDP-43 appear to aggregate in the cytoplasm, whereas they are 
normally mainly present and functional in the nucleus, a partial loss of (nuclear) function of 
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these proteins was thought to cause ALS. A complete loss of function seems unlikely, as 
complete knockout of either FUS or TARDBP is embryonically lethal in inbred animals (Hicks 
et al., 2000; Kraemer et al., 2010). For FUS, however, it is clear that disease occurs even when 
wild-type FUS is present at close to normal levels in the nucleus, indicating that a cytoplasmic 
gain-of-function mechanism is more likely (Mitchell et al., 2012; Sharma et al., 2016). 
Moreover, postnatal loss of FUS does not influence motor neuron survival, again implying a 
gain-of-function to underlie ALS (Sharma et al., 2016). 
Somewhat contrarily, for TDP-43 it appears that exclusion from the nucleus by 
inducible removal of the nuclear localization signal is sufficient to induce neurodegeneration 
(Walker et al., 2015). This leaves the question open whether neurodegeneration is triggered 
due to aberrant localization in the cytoplasm or due to loss of TDP-43 in the nucleus. However, 
an inducible post-natal knock-out of TDP-43 in mice results in death after 9 days (Chiang et 
al., 2010). This indicates that even if TDP-43 is absent from the nucleus in an ALS context, 
cytoplasmic TDP-43 presumably retains a physiological and necessary function for survival. 
Overexpression of TDP-43, however, causes an ALS-like phenotype, indicating that protein 
levels of TDP-43 need to be tightly regulated to prevent dysfunction (Wils et al., 2010). In 
summary, it appears that FUS mutations cause motor neuron death due to a toxic gain-of-
function in the cytoplasm. TARDBP mutations, on the other hand, most likely cause motor 
neuron degeneration due to both a loss-of-function in the nucleus, combined with a toxic gain-
of-function in the cytoplasm. It is important to identify where these different mechanisms 
intersect further downstream to result in motor neuron degeneration. 
 
1.2 SPINAL MUSCULAR ATROPHY 
 
SMA in its most severe forms (type 0 and I) is an infantile onset motor neuron disease, with 
death before 2 years of age. At the other end of the spectrum are type III and IV SMA, which 
have an onset later in life and often do not affect life expectancy, although patients are likely 
to become wheelchair-bound at some point in their life. 
 
Recent years have seen the development and approval of two breakthrough therapies: 
nusinersen (Spinraza, Finkel et al., 2016) and onasemnogene abeparvovec-xioi (Zolgensma, 
clinical studies still ongoing). Both treatments were shown to result in dramatic improvement 
in motor functions and lifespan, although the outcome seems highly dependent on the age of 




1.2.1 Genetics and disease mechanisms of SMA 
 
SMA is characterised by the progressive loss of lower motor neurons and resulting paralysis. 
In contrast to ALS, SMA is a monogenetic disease. It is caused by homozygous loss-of-
function mutations in the SMN1 gene (Lefebvre et al., 1995). In humans, a paralogous gene 
called SMN2 is present in varying copy numbers. This gene can partially compensate for the 
loss of SMN1. However, due to a single base pair substitution in SMN2 compared to SMN1 in 
exon 7, this exon is spliced out in approximately 90% of SMN2 transcripts, rendering it unstable 
(Lefebvre et al., 1995). Thus, the SMN2 gene only produces about 10% full-length SMN 
protein. As a result, patients with a loss-of-function of SMN1 develop SMA, while the copy 
number of SMN2 determines severity of disease, among likely other modifying factors 
(Harding et al., 2015). It is this process that nusinersen acts on, as it affects the splicing of 
SMN2, resulting in an increased proportion of transcripts from this gene that include exon 7. 
Zolgensma on the other hand is an AAV9 viral vector-mediated delivery of a fully functional 
copy of the SMN1 gene. 
 
SMN is known to perform a variety of functions in cells, being linked to translation, 
intracellular transport, endocytosis and more. However, the first and most well described role 
for SMN is in the nuclear biogenesis of snRNPs, by chaperoning the interaction between 
snRNAs and their accompanying proteins in nuclear structures termed ‘gems’ (Chaytow et al., 
2018; Liu et al., 1997). Subsequently, additional proteins and pre-mRNAs are added to this 
complex to form the spliceosome. Gems are not equally present in every tissue and their highest 
numbers are in fact present in neurons, particularly motor neurons, highlighting their 
importance for motor neuron diseases (Young et al., 2000). As the number of gems are reduced 
in SMA and this correlates with disease severity, splicing defects are thought to play an 
important role in SMA disease initiation (Gabanella et al., 2007). One particularly striking 
alteration in SMA is the preferred downregulation of components of the minor spliceosome 
(Gabanella et al., 2007). These complexes are required for splicing of minor introns, a subgroup 
that makes up only ~0.5% of all introns in humans. Genes containing minor introns are highly 
conserved and are involved in a subset of key cellular pathways, such as DNA damage repair, 
RNA processing and vesicle/axonal transport (Burge et al., 1998). 
 
SMN protein was also detected in axons and growth cones, where it is typically devoid of other 
protein components of the snRNPs or spliceosome, highlighting that it likely does not perform 
its canonical function here (Zhang et al., 2006). SMN was found to be responsible for mRNA 
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transport and regulation of local translation in axons, as well as cytoskeletal dynamics, mainly 
by modulating actin (Nölle et al., 2011).   
Several studies have linked FUS and TDP-43 to SMN, highlighting possible cross-disease 
pathways. FUS interacts directly with SMN, as it is also involved in the snRNP complex, 
specifically with U1 snRNP. FUS was shown to be required for gem formation, and in cells 
from both FUS and TDP-43 fALS patients, the number of nuclear gems was decreased, similar 
to SMA (Yamazaki et al., 2012). Furthermore, splicing alterations induced by loss of SMN had 
a significant overlap with those introduced by overexpression of human FUS in mice, which 
causes neurodegeneration (Mirra et al., 2017). FUS was shown to bind to U11 snRNP, thereby 
being directly involved in splicing of minor introns, similar to SMN. Splicing of these introns 
was defective upon expression of ALS-causative mutations in FUS (Reber et al., 2016). 
Together, this implicates minor spliceosome defects in the pathology of both SMA and ALS 
(Jutzi et al., 2018). 
 
Less is known about the interaction of TDP-43 with SMN or the spliceosomal complex. 
However, in TDP-43A315T mice an upregulation of SMN was observed, demonstrating a 
regulatory interaction between the two. SMN upregulation was likely a beneficial 
compensatory response, as overexpression of SMN in the TDP-43A315T context extended 
lifespan of the mice (Perera et al., 2016). 
 
1.3 DIFFERENTIAL VULNERABILITY OF SUBCELLULAR COMPARTMENTS 
 
The affected lower motor neurons in both ALS and SMA follow a distinct pattern of 
degeneration. Data from mouse models, as well as patient tissue, shows that the distal 
connection between motor neuron and muscle is lost first. This ‘dying-back’ pathology causes 
the muscle to be denervated, after which the motor neurons degenerate proximally, back to the 
soma (Cifuentes-Diaz et al., 2002; Fischer et al., 2004; Frey et al., 2000; Liu et al., 2015). This 
highlights the NMJ as a highly vulnerable element of the motor neuron. Processes culminating 
in axonal degeneration are likely driven by the soma, as is the case for trophic factor deprivation 
(Simon et al., 2016). However, preserving the NMJ as the initial site of degeneration can 
provide a therapeutic target to slow down progression of the disease. Moreover, rescuing motor 
neuron somas by preventing cell death does not protect against axonal degeneration and 




1.3.1 The motor axon contains a distinct mRNA composition 
 
While it is intuitive to think of the nucleus and cell body as the centre of the cell, this does not 
entirely hold true for motor neurons. With axons that can span up to a meter in length, an 
average spinal motor neuron holds more than 95% of its volume in the axon. The remainder is 
mostly taken up by dendrites, while only around 0.1% is contained in the soma. 
The large distance between the soma of a motor neuron and the NMJ implies that 
the distal axon must contain a distinct micro-environment to be able to rapidly respond to local 
cues. The fast-anterograde axonal transport system relies on kinesins and it carries vesicles and 
organelles at rates up to 40 cm per day. However, many soluble proteins and cytoskeletal 
elements travel considerably slower, at rates up to 1 cm per day (Lasek et al., 1984). This would 
not be sufficient to completely sustain the highly dynamic environment at the NMJ. Local 
storage of mRNA coupled with local translation could overcome this issue, allowing the distal 
axon to react to (environmental) cues by targeted translation and protein production. 
 
To investigate this, several techniques have been used to isolate distal axons and analyse their 
composition. Laser capture microdissection revealed the mRNA repertoire of growth cones of 
ex vivo cultured retinal ganglion cells (Zivraj et al., 2010). However, this technique required 
over 1,000 growth cones to be dissected to obtain sufficient RNA, although with current day 
methodologies this number could be reduced. An alternative method was to culture neurons in 
either Campenot or microfluidic chambers (Taylor et al., 2005). These allow for recruitment of 
axons by using trophic factor gradients and keep them isolated from the somas (see section 
3.2). Due to the size of these devices, material from several hundreds to thousands of axons 
can be harvested for analysis. Microarray-based detection of axonal RNAs was performed on 
various types of neurons, such as primary cortical (Taylor et al., 2009), sensory (Gumy et al., 
2011) and motor (Saal et al., 2014). These studies revealed the presence of up to 4,000 unique 
mRNAs in the axonal compartment. Subsequent studies utilized next-generation RNA 
sequencing, investigating rodent primary motor neurons and sensory neurons (Briese et al., 
2015; Minis et al., 2014) and found overlapping results. However, it was not clear what fraction 
of the detected axonal mRNAs is actually translated into proteins. 
To investigate this in developing retinal ganglion axons, Shigeoka et al. (2016) 
utilised a variant of TRAP (Translating Ribosome Affinity Purification). Here, one ribosome 
subunit is protein-tagged in a specific neuronal cell type. Pulldown of the tag and thus the 
ribosomes from the area to which these neurons project and subsequent RNA-sequencing of 
the mRNAs in these ribosomes revealed the axonal translatome at several time points. This 
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revealed that in adult mice, axonal translation occurs for just over 1,000 unique mRNAs, 
although it remains possible for mRNA transcripts to sit on ribosomes in a stalled state. At 
several time points during embryonic and early postnatal development up to 2,000 transcripts 
were being translated (Shigeoka et al., 2016). This shows that at most half of the unique 
mRNAs present in axons is actively translated at any given moment. The growing axon goes 
through successive phases of polarisation, outgrowth, pathfinding and synaptogenesis. It likely 
carries a repertoire of mRNAs along for all of these functions, to overcome delays that would 
otherwise arise from transport.  
 
1.4 MODELS OF MOTOR NEURON DISEASES 
 
1.4.1 Rodent models of ALS and SMA 
 
The discovery of SOD1 as the first causative gene in ALS in 1993 spurred the rapid 
development of a transgenic mouse model, based on the human SOD1G93A mutation (Gurney 
et al., 1994). This mouse model grew to become the most popular and widely used rodent 
model of ALS. It replicates the human disease progression well, as it displays an adult-onset 
hind limb paralysis that progressively worsens and is ultimately fatal. 
 
While different mouse strain backgrounds, as well as copy number of the SOD1G93A transgene 
can alter the time course of symptoms, the overall progression of disease is retained. Typically, 
the first behavioural symptoms are observed between postnatal day (P)60-80, with a decreased 
motor performance in the rotarod or hanging wire tests. Motor neuron somas in the spinal cord 
start to decrease in number as of P85-100, and end point survival is around 140-150 days 
(Fischer et al., 2004; Liu et al., 2015; Mancuso et al., 2012). 
 
This mouse model is in essence a model for SOD1-fALS, which lacks the otherwise so 
abundant TDP-43 inclusions seen in the vast majority of sporadic ALS cases. However, 
because the outward symptomatology and pathology is so similar between sALS and fALS, 
and indeed also SOD1-ALS and other types, it is thought that this model still holds value for 
ALS as a whole. This is reinforced by consensus findings that at the cellular level, similar stress 
pathways and events are seen in the SOD1G93A model as in post-mortem human ALS tissue, 
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such as ER stress, autophagy dysregulation and mitochondrial dysfunction. We utilised this 
mouse model in Paper I, and embryonic stem cells derived from this model in Paper IV. 
Recent years have now seen the development of mouse models based on known disease-
causing mutations in other genes, such as FUS (Sharma 2016), TARDBP (Walker et al., 2015) 
and C9orf72 (Liu et al., 2016). Hopefully this extended number of models will aid in the 
translation of more therapeutic avenues towards the clinic, as this aspect has been lacking from 
the SOD1G93A model. To illustrate, mice carrying a TDP-43 mutation were used to validate the 
therapeutic benefit of reducing levels of ataxin-2 (Becker et al., 2017), a genetic modifier of 
TDP-43 induced toxicity, identified in yeast (Elden et al., 2010). Similarly, antibody-mediated 
depletion of toxic dipeptide repeat proteins translated from the C9orf72 repeat region showed 
behavioural improvements and lifespan extension in C9orf72 mutant mice (Nguyen et al., 
2020).  
 
The discovery that autosomal recessive loss of the SMN1 gene caused SMA quickly led to 
efforts in generating a mouse model of this disease. However, while humans have two distinct 
copies of SMN, called SMN1 and SMN2, mice have only one single Smn gene. A complete loss-
of-function in mice, due to a homozygous deletion of Smn, is embryonically lethal (Schrank et 
al., 1997). Heterozygous depletion leads to mild motor neuron degeneration, and can serve as 
a model for SMA type III (Jablonka et al., 2000). However, to model the most severe type I 
SMA another strategy had to be employed. 
 It was shown that introducing the human SMN2 gene (that produces only 10% 
full length protein compared to human SMN1) into the mouse Smn-/- background could rescue 
the embryonic lethality, and mice survive for approximately 6 days (Monani et al., 2000). 
When subsequently a copy of human SMN∆7 is introduced, a pre-truncated form of SMN 
lacking exon 7, mice have an extended survival up to approximately two weeks (Le et al., 
2005). This effect requires small amounts of full-length SMN from the human SMN2 transgene 
to be present. Therefore, it is thought that SMN∆7 stabilises full length SMN, thereby exerting 
its beneficial effect. We used this mouse model, called the SMN∆7 model, in papers I and II. 
 
1.4.2 In vitro modelling of ALS 
 
Cell culture models of ALS assist in understanding and dissecting the mechanisms responsible 
for generating and maintaining a functional NMJ, as well as the processes that occur in motor 
neurons that ultimately lead to their demise in ALS and SMA. Here, murine and human 
pluripotent stem cells have provided a boost to the ALS field. In 2007, embryonic stem cells 
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(ESCs) were derived from the SOD1G93A mouse, the only available ALS model at the time. 
These cells could be differentiated into motor neurons using previously established protocols 
(Wichterle et al., 2002), and contained SOD1 positive inclusions in the cytoplasm, as is seen 
in SOD1-ALS port-mortem tissue from patients (Giorgio et al., 2007). Although the SOD1G93A 
motor neurons did show a mild increase in cell death compared to controls after a prolonged 
period in culture, they did not show gross morphological abnormalities or problems with 
differentiating into motor neurons. Their degeneration was accelerated upon co-culture with 
SOD1G93A-expressing astrocytes. These also affected the survival of control motor neurons, but 
to a lesser degree. Later, control human ES-derived motor neurons were also shown to be 
vulnerable in co-culture with glial cells carrying two different SOD1 mutations (Giorgio et al., 
2008; Marchetto et al., 2008).  
When human ES-derived motor neurons, but not other cell types in the culture, 
were expressing constructs carrying various SOD1 mutations, they exhibited a reduced survival 
and shorter neurite processes (Karumbayaram et al., 2009). This indicates that, even though 
non-cell-autonomous events can influence progression of degeneration, the initial trigger 
originates in the motor neurons themselves, justifying the use of motor neuron cell culture 
systems to study degenerative phenotypes.  
 
With the expansion of the human induced pluripotent stem cell (iPSC) field came the possibility 
to investigate and compare motor neurons derived from patient cells that carry mutations in 
other ALS-linked genes, as well as motor neurons derived from sporadic ALS patients. One 
goal was to be able to identify pathology in cells that did not rely on overexpression of a mutant 
gene, as is the case for the SOD1G93A mouse and stem cell models. 
 
Patient iPSC-derived motor neurons carrying TDP-43 mutations displayed increased cell death 
under regular culture conditions (Bilican et al., 2012; Fujimori et al., 2018; Kreiter et al., 2018) 
and arsenite-induced stress (Egawa et al., 2012). While others did not observe this 
degeneration, they did observe defects in neuronal firing properties and abnormal ion currents 
(Devlin et al., 2015). The differences in spontaneous cell death are likely partially dependent 
on the cell line and different culture conditions with varying levels of stress on the cells. 
Therefore, the use of CRISPR/Cas9 to edit out a mutation in a patient-derived line, or introduce 
it in a control genetic background could help reveal whether the specific mutation is responsible 
for any phenotypes observed, eliminating cell type and culture condition variables. This 
technique we utilised in Paper V. Cytoplasmic TDP-43 mislocalisation and aggregation was 
also observed in mutant iPSC-lines under stressor conditions (Fujimori et al., 2018; Zhang et 
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al., 2013), however this cell-autonomous degeneration in vitro has not been a consistent 
observation (Egawa et al., 2012, Kreiter et al., 2018). 
Two back to back papers showed that global downregulation of TDP-43, as well as expression 
of ALS-causative TDP-43 mutations led to a concomitant strong downregulation of stathmin-
2 (STMN2), due to splicing defects. Restoration of the levels of this microtubule regulator 
ameliorated disease phenotypes (Klim et al., 2019; Melamed et al., 2019). General defects in 
axonal transport and organelle trafficking were also found in TDP-43 mutant neurons in vitro 
and in vivo (Kreiter et al., 2018; Sleigh et al., 2020). Together, this highlights a cytoskeletal 
and particularly microtubule network disruption as a primary pathological process induced by 
TDP-43 dysfunction. However, this does not account for possible gain-of-function toxicity, as 
would occur in ALS patients that do not have a complete loss of TDP-43 function. 
 
Finally, in line with data from post-mortem tissue it was shown that sALS patient iPSC-derived 
motor neurons contained TDP-43 aggregates, whereas SOD1-fALS motor neurons did not 
(Burkhardt et al., 2013; Fujimori et al., 2018). Neurite outgrowth and survival defects were 
observed in a large number of the studied sALS lines (Fujimori et al., 2018). 
 
Regarding a non-cell-autonomous effect of TDP-43, studies were conducted in vitro to 
understand the roles of astrocytes and muscle carrying TDP-43 mutations. Human iPSC-
derived astrocytes carrying the TDP-43M337V mutation did not affect survival in co-culture of 
either wild-type motor neurons or motor neurons carrying the same mutation (Serio et al., 
2013). However, when mouse ESC-derived motor neurons were co-cultured with muscle 
overexpressing human TDP-43 mutations, increased motor neuron death was observed, albeit 
for one of the mutations only (Wächter et al., 2015). Whether this depends on TDP-43 levels, 
a genuine difference between astrocytes and muscle with regards to TDP-43 or simply different 
experimental settings is not clear. Experiments using non-overexpressing constructs will be 
needed to assess the relative contribution of different cell types to disease, although it is not 
unthinkable that central and peripheral exposure to non-cell autonomous toxicity can exert 
differential effects. 
 
IPSC-derived motor neurons that carry mutations in FUS are consistently reported to show 
mislocalisation of FUS to the cytoplasm, as well as occasional cytoplasmic aggregates. 
However, no spontaneous cell death has been observed (Ichiyanagi et al., 2016; Japtok et al., 
2015; Lenzi et al., 2015; Marrone et al., 2018; Naumann et al., 2018). Nonetheless, neurons 
carrying FUS mutations display various deleterious phenotypes, such as increased 
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susceptibility to oxidative stress (Ichiyanagi et al., 2016; Japtok et al., 2015; Marrone et al., 
2018), axonal fragmentation and increased susceptibility to DNA damage (Naumann et al., 
2018). 
 
Genetic correction of SOD1A4V patient-derived iPSCs revealed specific defects in the mutant 
cells in mitochondrial transport and morphology, as well as increased ER-stress and an 
activated unfolded protein response (Kiskinis et al., 2014). However, no detergent-insoluble 
SOD1 or SOD1 aggregates were detected in these motor neurons. The lack of aggregates was 
also observed in another study investigating the SOD1A4V and SOD1D90A mutations (Chen et 
al., 2014). More recently, two studies have shown misfolded and aggregated SOD1 in iPSC-
derived motor neurons (Fujimori et al., 2018; Imamura et al., 2017). This discrepancy could be 
explained by the use of different SOD1 mutations, as the latter two studies used L114FVX, 
H43R and H46R mutations. Genetic background of the lines can also play a role. However, 
differences in culture conditions may also form an equally likely explanation. Neurons in 
culture are easily stressed by oxidation, low density culturing, imperfect extracellular matrix 
conditions or lack of trophic support. Overall, mouse models of SOD1 mutations show a 
stronger SOD1 aggregation phenotype, even compared to post-mortem human ALS tissue. 
This is likely due to the forced overexpression of multiple copies of mutant SOD1 in mice. The 
process of misfolding and aggregation likely takes longer in the human cells, as SOD1 is only 
expressed at physiological levels. Hence the cases where SOD1 aggregates are observed may 
represent the more extreme end of the spectrum with stressed neurons displaying early 
pathological hallmarks. 
 
Several of the pathological hallmarks associated with C9ORF72-ALS have been recapitulated 
in in vitro models. Both RNA-foci as well as dipeptide repeat sequences arising through RAN-
translation were present in iPSC-derived neurons. These hallmarks were not only observed in 
motor neurons but also in other neurons, such as cortical glutamatergic, GABAergic and TH+ 
dopaminergic neurons (Almeida et al., 2013; Lopez-Gonzalez et al., 2016). These cells suffer 
from compromised mitochondrial function and a (presumably linked) increase in oxidative 
stress. Moreover, these cells become more vulnerable to autophagy inhibition, in line with 
recent papers describing a role for C9ORF72 in the initiation and regulation of autophagy 
(reviewed in Nassif et al., 2017). 
A transcriptomic comparison was made between dysregulated transcripts in 
C9orf72 repeat-carrying cells and controls and SOD1A4V carrying motor neurons (Donnelly et 
al., 2013; Kiskinis et al., 2014) and controls. This revealed only a 5% overlap in transcripts, 
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whereas there was a larger overlap between the SOD1 mutation and a different SOD1 mutant. 
This underlines the different aetiologies of SOD1- and C9ORF72-linked ALS. Overlapping 
pathways represent downstream events leading to neurodegeneration. However, early disease-
triggering mechanisms are likely to be very different between SOD1 and C9orf72-linked ALS.  
 
Taken together, the in vitro data show that pathological phenotypes such as protein aggregates, 
RNA foci and stress granules that are observed in post-mortem tissue from both mice and 
patients can be recapitulated in iPSC-derived motor neurons. However, these cell culture 
models typically only show minor morphological phenotypes or intrinsic degeneration under 
regular culture conditions. This makes sense, since these motor neurons are embryonic and 
fetal neurons that are used to model an adult-onset disease. The use of overexpression systems 
or the introduction of homozygous mutations (in contrast to the heterozygous mutations in 
patient cell lines) can provide the tools to study the initial pathological processes in motor 
neurons that might accumulate to trigger neurodegeneration later in life. 
 
1.5 DIFFERENTIAL VULNERABILITY OF MOTOR NEURON POOLS 
 
Curiously, most of the genes that are implicated in ALS and SMA are ubiquitously expressed 
throughout the body. Why mutations in these genes cause degeneration of specifically motor 
neurons is largely unclear. Moreover, certain subpopulations of motor neurons are more 
resistant to degeneration than others, while carrying the same genetic predisposition. Among 
the somatic motor neurons, oculomotor neurons that control eye movement typically remain 
resistant to degeneration until end stage of disease. This allows patients to utilize eye 
movements as a last means of communication (Caligari et al., 2013; Kubota et al., 2000; 
Lenglet et al., 2019). In addition, motor neurons of Onuf’s nucleus, involved in bladder and 
sphincter control, are affected to a lesser degree than surrounding sacral motor neurons 
(Bergmann et al., 1995). 
In mouse models of motor neuron disease, the selective resistance of the 
oculomotor system has been reproduced. At late stages of disease, oculomotor neurons are not 
lost, unlike other brainstem and spinal cord motor neurons (Ferrucci et al., 2010; Haenggeli 
and Kato, 2002). 
 
Oculomotor neurons differ from spinal motor neurons in some fundamental anatomical aspects 
(reviewed in Nijssen et al., 2017). One striking difference is that oculomotor neurons synapse 
onto multiple NMJs per muscle fibre in the extraocular muscles. This contrasts to all other 
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skeletal muscle in the body, where each myofibre is innervated by one single NMJ. 
Consequently, the extraocular muscles contain one band of neuromuscular endplates with the 
typical en plaque morphology, as seen in other skeletal muscles, but also a spatially separate 
band of so-called en grappe endplates. This innervation pattern is thought to allow graded 
contractions and a finer level of motor control compared to other skeletal muscles (Porter 
2002). 
 
In addition, the size of the motor units is distinctly smaller in oculomotor neurons, with a single 
one typically innervating only between 5-20 myofibres (Enoka, 1995; Gueritaud et al., 1985), 
while spinal motor neurons innervate in the hundreds of myofibres or even up to 2,000 in 
specific muscles (Burke and Tsairis, 1973; Burke et al., 1971). This is intriguing, as even within 
the spinal cord there appears to be a correlation with motor neurons having a smaller motor 
unit size being more resistant. Slow-twitch (S) motor units are comprised of ‘slow’ motor 
neurons innervating type I muscle fibres that are fatigue-resistant and have a highly oxidative 
metabolism. These motor units typically involve one motor neuron innervating 200 or fewer 
myofibres. In contrast, fast-twitch motor units (FF and FR) consist of motor neurons that 
innervate type IIa, IIb and IIx myofibres that are fatigable and glycolytic. It is these motor units 
that can have ratios of up to 2,000 muscle fibres innervated by one neuron (Burke and Tsairis, 
1973). In ALS, it is the ‘fast’ motor neurons that degenerate first, followed only late in disease 
by ‘slow’ motor neurons, that temporarily can compensate for loss of their fast neighbours 
(Hegedus et al., 2007; Pun et al., 2006; Schaefer et al., 2005). However, although the correlation 
is there, whether there exists a causal relation between the number of NMJs a motor neuron 
has to maintain and its vulnerability is unknown. 
 
Given the unique anatomy of oculomotor neurons and their resistance in disease, studies have 
investigated whether molecular differences confer their resilience. Mechanisms of proteostasis 
were different between oculomotor and spinal motor neurons, as oculomotor neurons appeared 
to have improved proteasomal function and thus an improved capacity to degrade misfolded 
proteins (An et al., 2019).  
Gene-expression profiling of spinal and oculomotor neurons in wild-type rats 
revealed an enrichment of potential protective factors in the oculomotor neurons (Hedlund et 
al., 2010). Several candidate genes from this study were followed up on, and later work showed 
that differences in mRNA levels of parvalbumin, Gucy1a3, GABAA receptor a1, insulin-like 
growth factor 2 (IGF-2) and synaptotagmin 13 were maintained at protein level in mouse and 
human post-mortem tissue (Allodi et al., 2016; Comley et al., 2015; Nizzardo et al., 2020). The 
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potential therapeutic effects of two candidate molecules, IGF-2 and SYT13, were explored 
further. In vitro, overexpression of either IGF-2 or SYT13 in iPSC-derived motor neurons from 
fALS and sALS patients improved their survival under glutamate-induced excitotoxicity or co-
culture with SOD1G93A mutant astrocytes. Similarly, it attenuated the spontaneous degeneration 
observed in iPSC-derived motor neurons from SMA patients. In vivo delivery of IGF-2 or 
SYT13 to motor neurons extended lifespan of a mouse models of ALS and SYT13 also 
improved survival of SMA mice, by preserving NMJ innervation and motor function for a 
prolonged period of time (Allodi et al., 2016; Nizzardo et al., 2020).  
Conversely, this paradigm was also used to identify factors highly expressed in the spinal motor 
neuron population, whose presence could explain their increased vulnerability. This strategy 
led to the identification of the matrix-metalloprotease Mmp9, a factor selectively expressed in 
fast motor neurons in mice. Reduction of Mmp9 levels in spinal motor neurons in SOD1G93A 
mice resulted in improved motor functions and extended lifespan, in a dose-dependent fashion 
(Kaplan et al., 2014).  Together, these strategies highlight the validity of identifying molecular 
differences between oculomotor and spinal motor neurons that confer increased resistance or 










The two main aims of this thesis were to investigate firstly why the subgroup of oculomotor 
neurons, among all somatic motor neurons, is intrinsically more resistant to degeneration in the 
motor neuron diseases ALS and SMA. Secondly, we explored the vulnerability of the distal 
axon, the first cellular part of the motor neuron to degenerate in ALS and SMA. The goal with 
our approach is to identify therapeutic targets and pathways aimed at improving motor neuron 
survival, as well as neuromuscular connectivity. 
Paper I: To validate oculomotor neuron resistance in two widely used mouse models of ALS 
and SMA, and to investigate the temporal dynamics of neuromuscular denervation. 
Paper II: To identify transcriptional mechanisms underlying resistance and susceptibility to 
degeneration in differentially vulnerable motor neuron pools in SMA. 
Paper III: To generate and characterise an in vitro model of oculomotor resistance in ALS. 
Paper IV: To develop a technique to study the motor axon transcriptome, and identify both 
how it differs from the somatic transcriptome and how it is dysregulated in an ALS context. 
Paper V: To investigate the effect of ALS-causative mutations in FUS and TDP-43 on the 







3 METHODOLOGICAL CONSIDERATIONS 
 
3.1 STEM CELL DIFFERENTIATIONS FOLLOW EMBRYONIC 
DEVELOPMENTAL PATTERNS 
 
Pluripotent stem cells come in two types: embryonic and induced. Both can differentiate into 
every type of cell in the body, the difference being their origins. Embryonic stem cells are 
extracted from the inner cell mass of a pre-implantation embryo, a technique that was first 
performed in 1981 in mice (Evans and Kaufman, 1981; Martin, 1981). Over the next two 
decades, research would focus on how to maintain ESCs in culture and subsequently generating 
protocols to differentiate ESCs into various cell types. The first human ESCs were isolated in 
1998 from embryos that were not used for implantation after successful in vitro fertilisation 
procedures (Thomson et al., 1998). Their limited availability spurred the field to identify novel 
ways of obtaining stem cells. In the early sixties experiments by John Gurdon already showed, 
using frogs, that the genetic material contained in a somatic cell has the capacity to replace the 
nucleus in a zygote and allow its differentiation into an entire organism (Gurdon, 1962). 
However, the challenge remained how to instruct a somatic cell to transform itself back into a 
stem cell and reinitiate all required processes for pluripotency. This was thought to require 
large-scale gene expression and chromatin reorganisation changes, and would go against the 
paradigm established by Waddington in 1957 describing that developmental gene expression 
and regulation is unidirectional (Waddington, 1957). 
The game-changing breakthrough came in 2006, when Shinya Yamanaka and 
colleagues identified four molecules that, when introduced into somatic cells of a mouse, could 
reprogram these cells into stem cells (Takahashi and Yamanaka, 2006). This feat was shortly 
after repeated for human cells (Takahashi et al., 2007; Yu et al., 2007). These factors, SOX2, 
KLF4, OCT4 and c-MYC effectively ‘de-differentiate’ somatic cells and allow the generation 
of stem cells from any individual. Their shared discoveries led to Gurdon and Yamanaka jointly 
winning the Nobel Prize in Physiology or Medicine in 2012. This new technique opened up the 
field of disease modelling immensely, providing the opportunity to obtain stem cells from 
disease patients and healthy controls for direct comparison. This is especially valuable in the 
neuroscience field, as neural tissue cannot be biopsied from living patients. Thus, stem cell-
derived neurons and neural tissues can provide a window to investigate disease processes in 
early stages that would otherwise be hardly accessible for research. 
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Spinal motor neurons were one of the early neuronal subtypes to be generated from mouse 
ESCs (Wichterle et al., 2002). This protocol employed two key factors that in combination 
were able to drive stem cells from neural induction to a definitive motor neuron fate: sonic 
hedgehog (Shh) and retinoic acid (RA). In embryonic development, RA is secreted by the 
somites that are adjacent to the newly formed neural tube. RA secretion is restricted, and its 
levels decrease anteriorly throughout the hindbrain. Thus, RA levels are highest in the 
developing spinal cord, decrease throughout the hindbrain and are absent anterior to the 
hindbrain-midbrain boundary (Maden, 2002). 
 Sonic hedgehog is released by the notochord, ventral to the developing neural 
tube. From there, it specifies the neural floor plate, which then in turn secretes Shh (Fig. 1A). 
This creates a gradient across the neural tube, with decreasing concentration from ventral to 
dorsal. This gradient enables a layered patterning that results in distinct domains along this 
gradient developing specific subgroups of interneurons, as well as motor neurons (Jessell, 
2000). 
The combined caudalising action of RA and the ventralising action of Shh can 
be utilised to control the type of neural cells generated and were fine-tuned to generate spinal 
motor neurons (Fig. 1B) (Wichterle et al., 2002). Using this paradigm, mostly cervical spinal 
motor neurons are generated. Patterning of further caudal spinal motor neurons has been 
achieved by integrating additional Wnt and Fgf8 signaling (Lippmann et al., 2015). 
 
For oculomotor neurons located in the midbrain, RA signalling was omitted, as caudalisation 
is not required in this protocol. Instead the cells are exposed to Fgf8, combined with Shh (Fig. 
1C). In vivo Fgf8 is secreted from the isthmic organizer, the boundary located between the 
developing midbrain and hindbrain (Heikinheimo et al., 1994). Gradients of Shh and Fgf8 
promote differentiation of neural progenitors to midbrain and hindbrain neurons, such as 
oculomotor neurons (Wang et al., 1995; Ye et al., 1998). Since the proportion of oculomotor 
neurons in the midbrain and consequently in stem cell-derived midbrain cultures is low, we 
employed a combined overexpression of the transcription factor Phox2a, a known driver of 






Figure 1. Different factors and gradients specify the developing midbrain and spinal cord. A. Schematic 
overview showing a sagittal cross-section of an embryo, and transverse sections of the midbrain and spinal cord. 
Retinoic acid (green) is released parallel to the spinal cord, while sonic hedgehog is released initially by the 
notochord and subsequently by the floorplate. Fgf8 is released at the isthmic organiser, at the separation between 
mid- and hindbrain. B. Differentiation protocols to specify cervical spinal motor neurons from mouse (top) and 
human (bottom) stem cells. C. Differentiation protocol to specify oculomotor neurons from mouse stem cells 
carrying the Nestin::Phox2A expression system. (A) Adapted from Allodi and Hedlund (2014) under the Creative 
Commons 3.0 licence. 
 
In 2005 the first motor neurons were generated from human embryonic stem cells (Li et al., 
2005) using the combined action of RA and Shh. While several studies used these cells, it was 
not until the advent of iPSC technology that motor neuron generation from human stem cells 
for disease modelling became its own research field. Several rounds of protocol optimisations 
have reduced the time to generate mature motor neurons from approximately one month down 
to 10-14 days. However, the key component of RA and Shh patterning remained virtually 
unchanged. 
 
Spontaneous neural induction occurs rapidly in mouse stem cells, but initially took up to two 
weeks for human cells. The discovery that combined inhibition of SMAD2/3 and SMAD1/5/8 
signalling caused rapid induction of neutral progenitors from human stem cells was a 
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breakthrough in the field (Chambers et al., 2009). This so-called dual-SMAD inhibition has 
become a highly used method to initiate conversion of human stem cells to any neural cell type. 
In the differentiation protocol used in Paper V, two days of dual-SMAD inhibition preceded 
one week of RA- and Shh-based patterning (Fig. 1B). 
A second advancement was made in the process of neural maturation. Both in 
our mouse and human protocols, cells are patterned with RA and Shh in a sphere-based culture, 
where aggregates of cells are floating freely in media. After the patterning period, these spheres 
contain committed OLIG2-positive motor neuron progenitors, but not yet mature motor 
neurons. Subsequent dissociation of the spheres and plating of the single-cell suspension on 
culture dishes then results in terminal differentiation into post-mitotic neurons. Inhibition of 
Notch-signaling was found to drive this transition and speed up the conversion of neural 
progenitors into mature motor neurons. An inhibitor of Notch signalling (DAPT), was 
consequently shown to cause a drastic reduction in the time of motor neuron generation, as 
well as increasing their proportion over other cell types, as it also avoids the progenitors from 
going into gliogenesis in a time-dependent manner (Maury et al., 2015).  
 
3.2 USING MICROFLUIDICS TO STUDY THE AXONAL TRANSCRIPTOME 
 
Three main methods have been developed to isolate neural cell bodies from axons. The first 
method to be developed was the Campenot chamber (Campenot, 1977). In this set-up, a solid 
divider (typically made from Teflon) is placed in a cell-culture dish and sealed to the bottom 
surface using a silicone grease layer, or in more recent versions, a hydrogel. When neurons are 
placed on one side of the divider, their processes can be recruited through the sealant using a 
gradient of trophic factors. While this method can be highly effective at isolating axons 
fluidically, it is time consuming and error-prone, as the divider can easily loosen and transect 
the axons growing underneath. 
 A second method is based on using well-insets in a traditional cell culture plate. 
Neurons are seeded on a porous membrane (typically made from PET or similar material) 
containing pores with diameters in the range of one to a few microns. This membrane is held 
in suspension in culture media, allowing neurons to grow processes that invade these pores and 
grow underneath the membrane. While in theory effective at maintaining a separation between 
soma and axon, this system allows cells that end up in suspension (for example during seeding 
or media changes) to adhere to the bottom of the membrane and ‘contaminate’ the neurites. In 
addition, growth of neural processes is not actively directed, making it hard to separate axons 
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from dendrites without distinct growth cues. Combined with the thin diameter of the 
membrane, contamination with dendrites or even cellular filopodia can occur. 
Lastly, microfluidic chambers made from silicone (typically PDMS) have been 
developed that can be sealed to a glass or plastic surface and form grooves for axons to grow 
through (Taylor et al., 2005). They typically contain 2 or more compartments for culturing the 
cells, with reservoir wells for media on the side (Fig. 2A). We have employed microfluidic 
devices with groove diameters of 3 micron in our studies. In these devices, a distinct 
neurotrophic gradient can be created to recruit axons. In addition, the length of the grooves can 
be as long as desired. We have employed 150 and 450 µm groove lengths. While dendrites in 
vitro can occasionally traverse the 150 µm grooves, they do not grow as long as 450 µm, 




Figure 2. Setup of using microfluidic chambers to culture motor neuron somas and axons in an isolated 
manner. A. Schematic of the devices. First motor neurons (MNs) are placed inside one of the compartment, after 
which a gradient of GDNF and BDNF is used to recruit axons to the second compartment. B. Hb9-GFP expression 
showing that the axonal compartment can be lysed without affecting the somas. Scale bar: B. 100 µm. 
 
A distinct advantage of the microfluidic system (as well as the Campenot chambers) over cell 
culture insets is that the two compartments are fluidically isolated. For one this allows the 
neurotrophic gradient, but it also allows for cells to be grown in entirely different medias (such 
as motor neurons and muscle cells) or receive different treatments either side. Importantly, they 
allowed us to lyse the axonal compartment, without affecting the somatic compartment or being 
contaminated with somas (Fig. 2B). Nonetheless, microfluidic devices have a lower throughput 
compared to insets, and due to their small size the number of cells that can be grown inside is 
limited. For certain assays (i.e. transcriptomics or proteomics) this results in too little material 
from single devices, requiring pooling of devices. To overcome this, we describe a technique 
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in Paper IV, Axon-Seq, that allows the RNA-sequencing of axonal material of one single 
device, due to the optimisation of a single-cell RNA library preparation protocol for axonal 
material. This has provided us the benefits of using the fluidically isolated chambers, while still 






4 RESULTS AND DISCUSSION 
 
The results in this thesis can be divided in two main parts, covered by papers I-III and IV-V, 
respectively. In the first three papers, we focussed on identifying pathways responsible for the 
selective resistance to degeneration of oculomotor neurons in ALS and SMA. 
We first demonstrated this resistance at the level of the NMJ in two mouse models of ALS and 
SMA, as well as describing a time course of NMJ denervation. Then we performed a 
transcriptomic study of differentially vulnerable motor neuron pools in the SMA mouse model, 
where we elucidated pathways of susceptibility or resistance. Thirdly, we generated an in vitro 
system, using mouse ESC-derived motor neurons, to model oculomotor neuron resistance in 
ALS. We showed that in vitro generated oculomotor and spinal motor neurons carry similarity 
to their in vivo counterparts, that the oculomotor neurons are more resilient under excitotoxic 
stress and that they express a survival-promoting signalling pathway. 
In papers IV and V we uncovered the rodent and human motor axon transcriptome, to study 
why the distal axon is the most vulnerable part of the motor neuron and why it degenerates first 
in disease. We showed that the motor axon contains a core set of mRNA transcripts for all 
essential cellular functions. In addition, dysregulation of the somatic and axonal transcriptomes 





4.1 PAPER I: CROSS-DISEASE COMPARISON OF AMYOTROPHIC LATERAL 
SCLEROSIS AND SPINAL MUSCULAR ATROPHY REVEALS 
CONSERVATION OF SELECTIVE VULNERABILITY BUT DIFFERENTIAL 
NEUROMUSCULAR JUNCTION PATHOLOGY 
 
In the SOD1G93A mouse model of ALS, oculomotor neurons were shown to persist while other 
brainstem and spinal cord motor neurons had degenerated (Ferrucci et al., 2010; Haenggeli and 
Kato, 2002). However, it had not been determined if this resistance held up at the level of the 
NMJ and if synaptic contacts were preserved. Moreover, in SMA mouse models, oculomotor 
resistance had not been thoroughly characterised at all yet. We set out to analyse in detail the 
dying-back phenotype in vivo and to perform an extensive analysis of NMJ denervation and 
post-synaptic morphology changes in two models of motor neuron disease. This also allowed 
us to pinpoint the order of events regarding pre-synaptic denervation and post-synaptic endplate 
changes in both ALS and SMA. We chose to investigate three muscle groups. Firstly, the 
extraocular muscles, innervated by the resistant oculomotor neurons. We chose lumbrical 
muscles, located in the paw of the mouse, innervated by lumbar spinal motor neurons for the 
reasons that they are innervated by a motor neuron pool that is known to be vulnerable to 
degeneration in disease, as well as the accessibility of these muscles for dissection and whole-
mount immunohistochemistry. Lastly, we chose the tongue, which is innervated by hypoglossal 
motor neurons (cranial nerve (CN) 12), as an indicator of bulbar involvement of disease. 
 
4.1.1 Extraocular muscles are resistant to denervation in the SOD1G93A model 
of ALS 
 
Denervation of NMJs was observed earliest in the lumbrical muscles at P84, before onset of 
symptoms in the mice, which is a confirmation of the vulnerability of the motor neurons 
innervating these muscles (Fig. 3A). Tongue muscle showed denervation only at the latest time 
point measured (Fig. 3E), while extraocular muscles showed no signs of NMJ pathology (Fig. 
3I). 
 
When assessing the size of the endplates on the muscle, we found a shrinkage of endplates in 
lumbrical muscles as of P112, one time point later than denervation was seen (Fig. 3B). This 
implies that motor nerve retraction is the initial event, leaving the muscle denervated and 
triggering the endplates to shrink. No endplate shrinkage was observed in tongue and 






Figure 3.  Denervation and endplate shrinkage pathology in three muscle groups of SOD1G93A ALS mice. A. 
Percentage of fully innervated NMJs in lumbrical (hind limb) muscles. The ALS mice show a loss of innervation 
as of P84. B. Average endplate area in lumbrical muscles. Endplates show shrinkage only as of P112, after NMJ 
innervation has been lost. C, D. Representative micrographs of lumbrical NMJs at P133 in ALS mice and controls. 
E. Percentage of fully innervated NMJs in tongues. No significant denervation is observed up to P133 in ALS 
mice. F. Average endplate area in tongue muscles. No shrinkage is observed at any time point. Also note that 
tongue NMJs are less than half the size even in control mice compared to lumbrical or extraocular NMJs. G, H. 
Representative micrographs of NMJs in tongue muscles in control and ALS mice. I. Percentage of fully innervated 
NMJs in extraocular muscle. No denervation is seen in extraocular muscles of the SOD1G93A mice. J. Endplate 
area of extraocular muscle NMJs. No shrinkage is present in these muscles. K, L. Representative micrographs 
showing NMJs in extraocular muscle. ** p < 0.01, *** p < 0.001, **** p < 0.0001. Scale bar: L: 40 µm, also 




4.1.2 Pre- and postsynaptic pathologies occur in parallel in the SMN∆7 model 
of SMA 
 
In the SMA model, NMJ denervation was observed only in lumbrical muscles, and only at the 
latest P14 time point (Fig. 4A). This is late, given the observable symptoms in the mice as of 
P5-6. Therefore, we looked at an additional neuromuscular pathology: neurofilament (NF) 
accumulation at the NMJ (Cifuentes-Diaz et al., 2002), thought to impair synaptic transmission 
before denervation occurs. We observed a strong increase in NF accumulation as of P10, again 
exclusively in the lumbricals. We did not observe this in the ALS model. This indicates that 
presynaptic dysfunction separate from denervation is part of SMA pathology. 
Interestingly, a decrease in endplate size was present at P10 (Fig. 4B), before any observable 
denervation. In addition, endplate maturation, as determined by the number of perforations 
within the endplate, was delayed in SMA mice already at P10. Additionally, taking the NF 
accumulation into account, starting at P10, this reveals that pre- and postsynaptic pathology in 
SMA mice occur at the same time, unlike in ALS. 
 No denervation and shrinkage were observed in tongue muscles (Fig. 4E, F) and 
extraocular muscles (Fig. 4I, J). The exception is that from P10 to P14, extraocular NMJs do 
not grow anymore in the SMA mice, unlike in the controls. This likely due to a general lack of 
growth in the SMA mice, as they are much smaller than their littermates at this time point. 
NMJs reach their maximum size between P10 and P14 in the SMA mice. This plateau only 
appears in the extraocular NMJs, because, compared to the other muscle groups NMJs are 
biggest in this muscle group. 
 
Taken together, we validated the resistance of oculomotor neurons to degeneration both in the 
SOD1G93A mouse model of ALS and the SMN∆7 model of SMA, by demonstrating that these 
neurons retained NMJ innervation until late stages of disease. Furthermore, we showed a 
temporal difference in the sequence of events between ALS and SMA. Whereas in the ALS 
model motor neuron denervation preceded shrinkage of the postsynaptic endplate on the 
muscle, these events occurred simultaneously in SMA. This implies that motor neuron-intrinsic 
processes contribute more strongly to the pathophysiology of ALS, while in SMA processes in 
both motor neurons and muscle appear to simultaneously contribute to pathology. Moreover, 
endplates did not mature at the same rate in vulnerable lumbrical muscles in the SMA model 






Figure 4. Denervation and endplate shrinkage pathology in three muscle groups of SMND7 SMA mice. A. 
Percentage of innervated NMJs in lumbrical muscles. The SMA mice show decreased innervation only at P14. B. 
Average endplate area in lumbrical muscles. Endplates show shrinkage already from P10, before NMJ innervation 
is lost. C, D. Representative micrographs of lumbrical NMJs at P14 in SMA mice and controls. E. Percentage of 
fully innervated NMJs in tongues. No significant denervation is observed up to P14. F. Average endplate area in 
tongue muscles. No shrinkage is observed at any time point. G, H. Representative micrographs of NMJs in tongue 
muscles in control. I. Percentage of fully innervated NMJs in extraocular muscle. No denervation is seen in 
extraocular muscles at any time point. J. Endplate area of extraocular muscle NMJs. No shrinkage is present in 
these muscles, except at P14. However, this is likely rather a lack of growth, as SMA mice are generally much 
smaller than their littermates at this age. K, L. Representative micrographs showing NMJs in extraocular muscle. 






4.2 PAPER II: LCM-SEQ REVEALS UNIQUE TRANSCRIPTIONAL ADAPTATION 
MECHANISMS OF RESISTANT NEURONS IN SPINAL MUSCULAR 
ATROPHY 
 
With oculomotor resistance being maintained in the SMN∆7 mouse model of SMA, we sought 
to uncover pathways responsible for the relative susceptibility and resistance of these motor 
neurons in disease. Given the strong role of the SMN protein in the assembly of the 
spliceosomal machinery, it is highly relevant to investigate transcriptomic dysregulation as it 
might represent targetable early disease processes. Therefore, we conducted a large-scale 
transcriptomic study to map gene regulation in resistant and vulnerable motor neuron pools in 
this model. Several groups of motor neurons were studied: vulnerable spinal and facial motor 
neurons (CN7), resistant oculomotor (CN3/4) and hypoglossal motor neurons (CN12) and 
resistant visceral motor neurons (vagus nerve, CN10). In addition, neurons from the red nucleus 
were included as a non-motor neuron control.  
To examine these specific cells in isolation, we employed laser capture 
microdissection (LCM) coupled with RNA sequencing (LCM-seq, Fig. 5). LCM is a powerful 
tool that allows tissue dissection at microscopic levels, thereby increasing the power of RNA-
sequencing of post-mortem tissue by having highly pure fractions of individual cells of interest. 
Our lab has demonstrated that LCM-seq can be performed down to the level of single isolated 
cells, when coupled with the Smart-seq2 protocol for cDNA library preparation (Nichterwitz 
et al., 2016, 2018; Picelli et al., 2013). While the technique has a drawback in that due to 3’-
bias of transcripts it is not optimised to investigate splicing differences, it is still highly accurate 




Fig 5. Overview of the LCM-seq procedure. Tissue is collected from the mice and sectioned in a cryostat. Then 
at the LCM-microscope the cells are isolated and subsequently cDNA libraries are made for RNA-sequencing. 
 
 33 
In this manuscript, we collected pools of up to 120 cells per motor nucleus to gain information 
on the general transcriptome differences between nuclei and pinpoint patterns related to 
selective resistance or vulnerability across motor neuron pools. Neurons were collected at 3 
different ages of the mice. We selected P2 (pre-symptomatic), P5 (early symptomatic) and P10 
(late symptomatic) time points to understand the dynamics of the transcriptome in resilient and 
vulnerable neurons. 
4.2.1 Transcriptomic changes in SMA mice are not confounded by a 
developmental deficit 
 
To assess whether disease-related changes were confounded by age-related changes, weighted 
gene correlation network analysis (WGCNA) was performed, and gene sets were isolated that 
correlated with time (i.e. either overall increasing or decreasing in expression from P2 to P10). 
Gene ontology (GO) analysis revealed an enrichment of the term ‘development’ among these 
genes. Principal component analysis based on only these ‘GO-developmental’ genes did not 
clearly distinguish SMA from control samples at P2 and P5, and only slightly at P10. However, 
at P10 the mice are highly symptomatic, and segregation here is likely driven by ongoing 
disease mechanisms. Together, this shows that gene expression differences that naturally occur 
over time during development do not differ strongly between SMA and control mice. This 
implies that at the transcriptional level the SMA mice are not in another (delayed) 
developmental phase. 
 Furthermore, we analysed the progressive development of NMJs to exclude a 
peripheral developmental phenotype. Single NMJs at P0 are poly-innervated by multiple motor 
axons simultaneously. These are pruned back during the first 2 postnatal weeks, until there is 
only a single axon remaining. Also post-synaptic endplate densities undergo progressive 
change. Initially they appear as homogenous plaques, but they gain perforations as they take 
on a more complex morphology in the first 2 postnatal weeks. We used the number of poly-
innervations (Fig. 6A) and endplate perforations (Fig. 6C) as measures for developmental 
maturity. Based on these traits, SMA mice show no overt phenotype up to P10 in extra-ocular 
muscles (innervated by CN3/4), tongue (innervated by CN12) and lumbrical muscles 
(innervated by lumbar spinal motor neurons) for either poly-innervation (Fig. 6B) and endplate 
perforations (Fig. 6D). Only at P14, the humane terminal endpoint for these mice, the lumbrical 
muscles in SMA mice show deterioration and a severe lack of complex morphology compared 




Combined, this gene expression data coupled with the peripheral NMJ analysis demonstrates 




Figure 6. Analysis of development of the motor system in SMA mice. A. Micrograph of an NMJ showing poly-
innervation, where multiple axons innervate one single endplate. B. Percentages of mono-innervated, and thus 
most mature, NMJs in three muscle groups in the SMA mice. No differences are observed up to P10 with regards 
to poly-innervation. C. Micrograph of endplates in various degrees of maturation, as signified by their number of 
perforations. D. Average percentage of endplates presenting with 0, 1, 2 or 3 perforations in three muscle groups. 
Only at P14 do SMA mice show a difference from controls, likely due to disease processes disrupting the NMJs. 
Scale bars: A and C: 10 µm. 
 
4.2.2 Somatic motor neurons have both common and unique responses to 
loss of Smn 
 
Comparisons between SMA and control motor neurons at every time point for every cell type 
revealed an early change in gene regulation in mainly CN3/4 and CN12 at the early stage (P2), 
with the highest number of differentially expressed genes (DEGs) at this time point. At P10, 
however, CN3/4, CN7 and spinal motor neurons had the largest dysregulation of genes, as the 
number of DEGs per cell type increased from P2. Very few DEGs were detected in the non-
disease affected red nucleus neurons, as well as visceral CN10 motor neurons (Fig. 7A). 
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Surprisingly, also hypoglossal CN12 neurons showed fewer DEGs than the other somatic 
motor neuron pools, both resistant and vulnerable. When combining DEGs of all 3 time points 
within each cell type it became evident that, although there is some overlap, most differential 
gene regulation is unique to each neuron type, implying that neurons cope with Smn-deficiency 
in various ways (Fig. 7B). 
 
Taking a step back from individual genes, we once again used WGCNA to identify a gene 
cluster comprised of 251 genes that was correlated to disease in the somatic motor neuron 
groups, across all time points (Fig. 7C). Principal component analysis based on these genes 
was unable to segregate SMA from control samples in the non-affected CN10 and red nucleus 
neurons. This indicates that this module of genes is specific to somatic motor neurons, 
irrespective of their relative vulnerability. 
Among the GO-terms that were enriched in the genes of this module were p53-
induced signalling and apoptosis-related signalling (Fig. 7D). Accordingly, GO-term analysis 
also showed similar enrichment for p53- and apoptosis-related terms when using DEGs as input 
between control and SMA at P10 in CN3/4, CN7 and spinal cord. Interestingly, even at P5 
spinal cord DEGs show an enrichment for these terms. 
This indicates that we have uncovered a common disease signature within 






Figure 7. Analysis of gene expression changes in the SMND7 mouse model. A. Number of differentially 
expressed genes (DEGs) between control and SMA for each nucleus and time point. Bar above and below zero 
represents up and downregulated genes. The number represents the total number of DEGs. B. Venn-diagram of 
overlapping DEGs between nuclei, with all time points combined. x/y represents x commonly upregulated and y 
commonly downregulated genes in SMA. C. Mean eigengene value of the WGCNA-identified disease module for 
all nuclei and time points. This shows the expression of genes in the disease module increases only in the somatic 
motor neurons in the SMA mice. D. Selected GO terms for the genes in the disease module (C). 
 
4.2.3 Resistant oculomotor neurons have a distinct transcriptional signature 
that could confer resistance 
 
Intriguingly, resistant CN3/4 also showed upregulation of apoptotic pathways as well, albeit at 
later stages than in spinal motor neurons. Subsequently, this group was compared more 
extensively to the vulnerable spinal motor neurons. STRING analysis for protein-protein 
interactions showed that of the DEGs at P10 in CN3/4, 46.7% could be embedded in an 
interconnected interaction network. For spinal motor neurons 35.5% of the genes were 
interconnected, and spread over two networks. While both spinal cord and CN3/4 showed 
upregulation of DNA damage sensing and repair proteins (Trp53 and Polk), CN3/4 showed a 
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specific upregulation of pro-survival factors such as Pak4, Pak6, Gdf15 and Chl1. This was 




Figure 8. Overview of key genes and their associated functions identified through our LCM-seq analysis. 
A. Key genes dysregulated in oculomotor neurons between SMA and control. B. Key genes dysregulated in spinal 
motor neurons between SMA and control. Colour represents significance value. C. Schematic of pathways that 
some of the key genes in (A) and (B) are involved in that may explain their possible conferred resistance or 
vulnerability.  
 
Moreover, CN3/4 neurons showed an enrichment of synaptic proteins in disease that are linked 
to improved neurotransmission (Syt1, Syt5 and Cplx2), as well as factors positively influencing 
neurite outgrowth and re-innervation (Gap43, Chl1, Cald1 and Serpine2) (Fig. 8A, C). Spinal 
motor neurons, on the other hand, showed specific enrichment for cytoskeleton destabilising 
proteins (Inf2 and Tubb6), as well as decreased mRNA levels of key motor proteins (Kif3a and 
Kif5a) (Fig. 8B, C).  
Finally, we selected Gdf15 as a candidate to confirm our hypothesis that factors 
upregulated in resilient neurons can protect more vulnerable neurons. Toward this goal we 
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generated vulnerable human spinal motor neurons from iPSCs (Fig. 9A) and cultured them in 
a trophic factor deprivation assay, leading to neuronal death over time (Fig. 9B). Exposing the 
neurons to different concentrations of GDF15 improved their survival in a dose-dependent 
manner in all but the last time point measured (Fig. 9C-F). 
 
Taken together, this shows that the resistant and vulnerable somatic motor neuron populations 
have distinct mechanisms to cope with Smn-deficiency, resulting in either a pro-survival 
cascade in CN3/4 or a negative cascade leading to neurodegeneration in spinal motor neurons. 
We also show that a pro-survival factor, Gdf15, that was upregulated in resistant CN3/4 motor 






Figure 9. GDF15, a factor enriched in oculomotor neurons in SMA, can protect vulnerable spinal motor 
neurons. A. Schematic overview of the experimental procedures. GDF15 was added from day in vitro (DIV) 21 
forwards and cells were analysed at DIV 35, 42 and 49. B. Untreated motor neurons degenerate over time, as also 
shown in the representative micrograph images. C-E. Percent of surviving motor neurons normalised to the 
untreated condition. GDF15 at both 50 and 200 ng/ml resulted in significantly improved survival at DIV 35 and 
42. F. Representative images at DIV42 showing the enhanced survival of motor neurons cultured in the presence 





4.3 PAPER III: MODELING MOTOR NEURON RESILIENCE IN ALS USING STEM 
CELLS 
 
We sought to utilise the potential of oculomotor resistance in ALS as a discovery tool and 
generate an in vitro model of this selective vulnerability. This would allow for an additional 
angle to uncover and investigate candidate genes and pathways responsible for the protection 
of oculomotor neurons in ALS. 
 
4.3.1 Mouse embryonic stem cells can be differentiated into oculomotor 
neurons 
 
Oculomotor neurons are specified in the ventral midbrain by the combined actions of the 
morphogens sonic hedgehog (Shh), Fgf8 and Wnt. These signals then trigger the expression of 
transcription factors such as Phox2a and Phox2b, that further specify and determine 
oculomotor neuron fate (Deng et al., 2011; Pattyn et al., 1997). To generate oculomotor neurons 
in vitro, we adapted a protocol involving the patterning of mouse ESCs by exposure to Shh and 
Fgf8, combined with an overexpression of Phox2a (Mong et al., 2014). The overexpression 
was driven by the nestin-promoter, ensuring a pan-neural progenitor activation. In parallel, we 
utilised an established protocol to generate spinal motor neurons (Wichterle et al., 2002), based 
on patterning with Shh and retinoic acid.  
 
Utilising overexpression of Phox2a (combined with Ngn2 and Isl1) has been used before to 
generate midbrain motor neurons in the absence of the external patterning factors Shh and Fgf8 
(Mazzoni et al., 2013). However, microarray data from the 2013 study showed expression of 
Mnx1 (Hb9), a marker that is classically absent in oculomotor neurons (Guidato et al., 2003). 
The exact brainstem neuronal population was not defined in this protocol, and it might have 
been a mix of oculomotor neurons along with motor neurons from other brainstem nuclei, such 
as trigeminal (CN5) or facial (CN7). 
In our cultures, we showed, using immunocytochemistry, that half of the neurons 
in our oculomotor cultures expressed Isl1, an established marker for motor neurons at all 
anterior-posterior levels (Fig. 10A-C). Of these motor neurons, less than 10% expressed Mnx1. 
In contrast, in the spinal motor neuron cultures 60% of Isl1+ cells co-expressed Mnx1 (Fig. 
10C).  
 
To further validate the identity of our in vitro generated spinal and oculomotor neurons, we 
conducted a transcriptomic analysis on GFP-purified fractions of these cultures. Using an Hb9-
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GFP line for spinal motor neurons and an Isl1-GFP line for oculomotor neurons (as they lack 
Hb9), we could isolate motor neurons from both subpopulations using flow sorting and perform 
bulk RNA sequencing. 
 This revealed that, as expected, classical neuronal markers were expressed, as 
well as specific combination of markers for the midbrain oculomotor neurons (Isl1, Phox2a, 
Phox2b) and spinal motor neurons (Isl1, Mnx1, Lhx1, Lhx3, Olig1, Olig2) (Fig. 10D). 
Furthermore, the differentially expressed genes between our purified spinal and oculomotor 
neurons could cleanly separate published RNA-sequencing data from laser-capture 
microdissected spinal- and oculomotor neurons of early post-natal and adult rodents (Hedlund 
et al., 2010; Kaplan et al., 2014) (Fig. 10E, F).  
 We performed an unbiased gene clustering approach using the Pathway and 
Gene Set Overdispersion Analysis (PAGODA) algorithm to elucidate gene sets specific to 
either our entire midbrain and spinal cord cultures (including GFP-positive motor neurons as 
well as GFP-negative cells), or to the respective GFP-positive motor neuron groups only (Fig. 
10G, H). This way, we were able to separate the differentially expressed genes between spinal 
motor neurons and oculomotor neurons (green circles in Fig. 10G, oculomotor enriched, and 
H, spinal motor neuron enriched) in two groups: genes that reflected a difference between the 
two cultures (midbrain / spinal cord) and those genes that were specific to oculomotor neurons 
or spinal motor neurons. This analysis revealed that some of the differentially expressed genes 
only reflected differences between midbrain and spinal cord and the anterior-posterior axis (e.g. 
Phox2a and Hox-genes, blue circles in Fig. 10G, H). When pinpointing the motor neuron-
specific genes (orange circles in Fig. 10G, H), we confirmed, among others, the specificity of 
Mnx1 for spinal motor neurons but not other cells in our ‘spinal’ cultures, while identifying 
several genes including Eya1, Eya2, Sema6d and Rgs4 to be specific to oculomotor neurons, 





Figure 10: In vitro derived oculomotor neurons resemble their in vivo counterparts. A,B. Micrographs 
showing immunocytochemical staining of motor neurons generated with the spinal and oculomotor protocols. 
Spinal motor neurons express Hb9 and Islet1, while our in vitro generated oculomotor neurons lack Hb9 
expression. C. Quantification showing the lack of Hb9-expression in the oculomotor neurons. D. Selection of 
classical (motor) neuronal marker genes, as well as genes that are more specific to oculomotor or spinal motor 
neurons. E, F. Using the top 100 differentially expressed genes between our oculomotor and spinal motor neurons, 
we could separate microarray data from early post-natal (E) and adult (F) in vivo rodent oculomotor and spinal 
motor neurons. G, H. Visualisation of the pathway and geneset overdispersion analysis (PAGODA) on all our 
samples, i.e. GFP-sorted motor neurons from both spinal and oculomotor cultures, as well as GFP-negative cells 





4.3.2 In vitro oculomotor neurons are more resilient during excitotoxicity 
 
One of the downstream events in ALS is thought to be glutamate-driven excitotoxicity. 
Therefore, we exposed our two types of motor neurons to excitotoxic stress using kainic acid, 
an agonist of glutamate receptors. In the face of this stress, oculomotor neurons survived better 
than spinal motor neurons (Fig. 11A-C). In addition, oculomotor neurons did not change the 
length and branching of their processes, indicating that no axonal or dendritic degeneration was 
occurring. 
 
To explain this resistance, we turned again to the RNA sequencing data. Here we found that 
oculomotor neurons have an increased expression of calcium-buffering transcripts such as 
Cald1, Esyt1 and Camk2a. A higher calcium-buffering capacity has previously been mentioned 
as one factor explaining oculomotor neuron resistance in ALS (Vanselow and Keller, 2000). 
We also observed increased levels of Akt signalling, as exemplified by higher expression levels 
of Akt1 and Akt3, and higher protein levels of phosphorylated Akt (Fig. 11D-F) and β-catenin 
(Fig. 11 G-I). Our group has previously shown the importance of pro-survival AKT-signalling 
in motor neuron resilience after treatment with insulin-like growth factor 2 (IGF2), a factor that 
was discovered based on an in vivo transcriptomic screen between laser-capture microdissected 
spinal and oculomotor neurons in rats (Allodi and Hedlund, 2014; Hedlund et al., 2010). 
 
We subsequently showed that AKT signalling is also elevated in human post-mortem laser-
capture microdissected oculomotor neurons compared to spinal motor neurons (Fig. 11J). 
However, this was not the case in motor neurons from Onuf’s nucleus, a small group of neurons 
in the sacral spinal cord that are also resistant to degeneration in ALS (Mannen et al., 1982). 
This implies that the higher levels of pro-survival Akt signalling are an oculomotor-specific 
protection mechanism (Fig. 11K). 
 
In conclusion, this paper demonstrated that the resistance of the oculomotor system observed 
in ALS patients and rodent models of disease can also be recapitulated in vitro, and that these 
stem-cell derived motor neurons can serve as tools to uncover new protective factors in 





Figure 11: Oculomotor neurons are more resistant to excitotoxicity and have increased pro-survival Akt-
signalling. A,B. Micrographs showing spinal and oculomotor neuron cultures after 7 days of exposure to 20 µM 
kainic acid. C. Quantification of surviving motor neurons, by islet-1 staining. Oculomotor neurons survive better 
in the face of excitotoxicity than spinal motor neurons. D, E. Images showing increased staining for 
phosphorylated Akt in oculomotor neurons compared to spinal motor neurons. F. Quantification of phosphorylated 
Akt staining. Oculomotor neurons maintain phosphorylated Akt in excitotoxic conditions. G, H. Images showing 
increased presence of beta-catenin in oculomotor neurons compared to spinal motor neurons. I. Quantification of 
beta-catenin staining. Again, oculomotor neurons maintain beta-catenin during excitotoxicity. J. Expression levels 
of AKT3 in human spinal motor neurons, oculomotor neurons and neurons of Onuf’s nucleus. K. Venn diagram 
of differentially expressed genes between oculomotor neurons and Onuf’s nucleus neurons, both compared to 




4.4 PAPER IV: AXON-SEQ DECODES THE MOTOR AXON TRANSCRIPTOME 
AND ITS MODULATION IN RESPONSE TO ALS 
 
In Paper IV, we shifted our focus to understanding why specifically the distal axon is a highly 
vulnerable compartment of motor neurons. Towards this goal we developed a method called 
Axon-Seq, to allow the investigation of the axonal transcriptome separated from the somatic 
(cell body) transcriptome. 
 
We generated spinal motor neurons from mouse ESCs (see section 3.1). Microfluidic culturing 
of these motor neurons was used to separate axons from somas (see section 3.2). To allow 
RNA-sequencing to be performed on single devices, concentration of the axonal lysate was 
combined with optimisation of the Smart-Seq2 protocol for library preparation. Together, we 
managed to generate cDNA libraries from single device axon preparations. 
 First, we assessed the overall size of the axonal transcriptome and found that the 
number of uniquely detected transcripts in axons was lower than in somas. Axons expressed 
on average around 5,000 transcripts, compared to 15-17,000 in somas (Fig. 12A). We also 
noticed that some axonal samples appeared to have an increased number of detected genes. 
Analysis of marker gene expression and unbiased clustering led us to the conclusion that these 
samples were likely contaminated with one or more cells that shifted the transcriptome entirely. 
We then proceeded to routinely and thoroughly check all samples for somatic contamination. 
 
4.4.1 The axonal transcriptome contains mRNAs for essential cellular 
functions 
 
Several hundred transcripts were enriched in the axonal compared to the somatic transcriptome. 
We found strong overrepresentation of transcripts encoding proteins for essential cellular 
functions, such as ribosomal subunits and components of the mitochondrial respiratory electron 
transport chain, even in only the top 25 most axon-enriched transcripts (Fig. 12B). This makes 
sense, as mitochondria can multiply by fission in axons (Amiri and Hollenbeck, 2008). 
However, they would need to locally build up their repertoire of proteins for energy production. 
Local translation of these mRNAs would allow for an energy and storage-efficient way of 
coping with this. Gene set enrichment analysis confirmed the enrichment of the complete 
respiratory electron transport pathways in axons (Fig. 12C). As for ribosomal subunits, we also 
detected essentially the entire pathway Ribosome enriched in axons (Fig. 12D). It was long 
unknown whether ribosomes can be created in axons, as the presence of their subunits at 
mRNA level would suggest. Ribosome biogenesis traditionally occurs in the nucleolus, where 
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rRNA and proteins come together and are assembled into the small and large components 
(reviewed in Peña et al., 2017). Subsequently, mRNAs are then shuttled into axons already 
loaded on polysomes, essentially carrying ribosomes along from the start (Crispino et al., 
1997). Additionally, ribosome components (completed small and large subunits) can be 
transferred from adjacent glia, such as Schwann cells, into axons (Court et al., 2008). However, 
recently it was demonstrated that fully functional ribosomes can exchange subunits in axons, 
and local translation of these individual ribosome subunits might therefore benefit the local 




Figure 12. General characteristics of the motor axonal transcriptome. A. Number of uniquely detected genes 
in mouse ESC-derived motor neuron somas and axons. B. Heatmap showing the expression in axons and somas 
of the top 25 most axon-enriched genes. A large number of these genes encode mitochondrial proteins or ribosomal 
subunits. C,D. Gene set enrichment analysis plots showing an axonal enrichment of the pathways respiratory 
electron transport and ribosome.  
 
An interesting finding was the localisation of a number of transcription factor mRNAs into 
axons. There is considerable overlap among the highest expressed transcription factors in 
somas and axons, even though they may perform entirely different functions in the different 
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subcellular compartments. As such, axons appear to have a repertoire of specific local 
transcription factors than possibly perform non-canonical roles rather than their classical role 
as a DNA-binding factor. For example, the most axon-enriched transcription factor, Ybx1, is 
known to have roles in alternative splicing and mRNA transport (Lyabin et al., 2014). It’s very 
high expression in axons suggests that it has important local functions in mRNA metabolism. 
In addition, some of these transcription factors might be present locally as signalling/survival 
cues to other cells in vivo, e.g. Schwann cells or muscle. Along these lines, it was shown that 
targeted secretion of the homeobox family transcription factor Otx2 from one neuron to another 
can promote the receiver neuron’s survival (Kim et al., 2016). 
 
4.4.2 The ALS-causative SOD1G93A mutation causes dysregulation in the 
axonal transcriptome 
 
Finally, we set out to compare the axonal transcriptome of control mouse ESC-derived motor 
neurons with that of cells carrying the ALS-causative SOD1G93A mutation. We detected high 
expression of the SOD1G93A transgene both in cell bodies and in axons (Fig. 13A). This is not 
unexpected, as the endogenous Sod1 also is highly expressed in axons (Fig. 13B). We 
uncovered dysregulation of 121 genes in the SOD1G93A mutant motor axons (Fig. 13C). We 
cross-compared with published data of similar microfluidic chambers coupled with primary 
motor neurons, where Smn was knocked down as a model for SMA. We found 16 transcripts 
that were dysregulated across ALS and SMA, among which one commonly downregulated 
gene: Nrp1, a semaphorin co-receptor. These data indicate that loss of Nrp1 in axons could be 
an early disease phenotype across motor neuron diseases. 
 
Among the dysregulated transcripts in the SOD1G93A axons was also the RNA binding proteins 
Rbpms, which was shown to have a severe impact on axonal branching in retinal ganglion 
neurons (Hornberg et al., 2013), Dbn1, an actin-binding protein strongly involved in 
cytoskeleton remodelling in dendrites (Mizui et al., 2005) and Nek1, the function of which has 








Figure 13. Mutant SOD1G93A induces gene dysregulation in motor axons. A. Mutant human SOD1G93A is 
expressed in both somas and axons at very high levels (> 10,000 RPKM). B. Endogenous mouse Sod1 is enriched 
in axons and expressed at lower levels than the human SOD1, but nonetheless high (1,000 – 5,000 RPKM). C. 
Heatmap showing the 121 dysregulated transcripts in the SOD1G93A motor axons. 
 
4.4.3 Cross-comparison with published data reveals a core axonal 
transcriptome 
 
Throughout the paper we cross-compare our motor axon transcriptome with published datasets 
of axonal transcriptomes generated with RNA-sequencing. We compared to data from primary 
embryonic mouse motor neurons grown in microfluidic devices (Briese et al., 2016) or cell 
culture insets (Rotem et al., 2017), as well as sensory neuron axons from dorsal root ganglia 
grown on cell culture insets (Minis et al., 2014). One striking difference to us was that the 
number of detected genes in our axonal samples was drastically lower (~5,000) compared to 
all other datasets (10,000+) (Fig. 14A, B). In fact, all published datasets showed a similar 
number of transcripts in axons as in somas. We only observed these high numbers in axon 
samples that we deemed ‘contaminated’ with cell bodies. We then clustered all our samples, 
axons and somas, as well as those of published datasets together based on neuronal and glial 
marker genes (after remapping everything through the same pipeline to avoid mapping bias). 
Here we observed clustering of the published axon samples together with our soma samples, 
strengthening our suspicion of cellular contamination in the published axon samples (Fig. 14C). 
To analyse what made up the difference in number of detected genes, we ran GO-term analysis 
on the non-overlapping genes between the axonal samples in our data and the published 
datasets. This resulted in a clear enrichment of proliferative processes (DNA-dependent DNA 
replication, Mitotic nuclear division), confirming that these samples contained proliferative 





Figure 14. Cross-comparison with published axon transcriptomes reveals a core axonal mRNA pool. A. 
Venn diagram of genes detected in axons in this study and motor axons in Briese et al., 2016. Enriched GO-terms 
are shown on the side pertaining to the genes in the respective compartment. B. Comparison of the genes found to 
be overlapping in (A) with the axon-detected genes in DRG axons in Minis et al. (2014). Enriched GO-terms are 
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shown on the side pertaining to the genes in the respective compartment. C. Heatmap showing expression levels 
of marker genes in all published motor axon datasets (Briese et al., 2016; Rotem et al., 2017).  
 
However, we did manage to pinpoint a core motor axon mRNA pool through cross-comparison 
with the embryonic primary motor neurons (Briese et al., 2015; Rotem et al., 2017), as well as 
a core peripheral axon pool through cross-comparison with the sensory neurons (Minis et al., 
2014). These findings regarding sample purity were subsequently validated in a recent study 
looking at in vivo micro-dissected axons and cross-comparing with previous work including 
our study (Farias et al., 2020). Our dataset nearly completely overlapped with the core axon 
transcriptome reported in this study and subtle differences are likely due to developmental 
differences, e.g. myelination. 
 
In conclusion, we have developed a technique called Axon-Seq that is highly sensitive to detect 
axonal mRNAs. Coupled with a bioinformatic control step we can isolate pure axonal samples 
without cross-contamination of other cell types. We identify a high abundance of ribosomal 
and mitochondrial proteins among the axonal transcripts, in line with their essential functions 
in the neuron, as well as transcription factors, an exciting avenue for further research as they 
must perform a non-canonical function in axons. We show dysregulation of the axonal 
transcriptome in an ALS model based on the SOD1G93A mutation and through cross-
comparison with published datasets we can highlight a core motor axonal transcript pool of just 





4.5 PAPER V: MUTATIONS IN THE ALS-CAUSATIVE GENES FUS AND TDP-43 
CAUSE DISTINCT DYSREGULATION OF SOMATIC AND AXONAL 
TRANSCRIPTOMES 
 
In Paper V we furthered the microfluidic Axon-Seq platform that has been set up in Paper IV 
to investigate human iPSC-derived motor neurons carrying ALS-causative mutations in FUS 
and TDP-43. We adapted published protocols to generate a high proportion (~85%) mature 
spinal motor neurons from human iPSCs (see section 3.1). Next, we differentiated lines 
carrying homozygous FUSP525L, TDP-43M337V and FUS KO mutations into motor neurons to 
enable analysis of transcriptome dysregulation in somas and axons due to mutations in these 
RNA-binding proteins. 
 
4.5.1 Cellular distribution of FUS and TDP-43 is altered between our iPSC-
derived motor neurons 
 
Firstly, however, we investigated the distribution of FUS and TDP-43 themselves in the motor 
neurons carrying the ALS mutations. We observed a reduction in nuclear FUS, as well as overt 
mislocalisation to the cytoplasm in the FUSP525L line. This is expected, given that this mutation 
perturbs the nuclear localisation signal and effectively maintains FUS outside of the nucleus. 
Interestingly, also the TDP-43M337V line displayed a reduction in nuclear FUS, but no 
cytoplasmic mislocalisation, indicating a crosstalk between the two proteins. 
The TDP-43M337V line also displayed a reduction in nuclear TDP-43 signal, but 
without mislocalisation to the cytoplasm. This mutation does not directly affect nuclear 
localisation, as it is located in the glycine-rich domain of TDP-43. Thus, this reduction is not 
directly caused by mislocalisation, but rather other processes that render the protein less 
detectable. RNA levels of TDP-43 were not altered, yet decreased translation efficiency 
remains a possibility. Alternatively, given that the TDP-43M337V mutations renders the protein 
more prone to aggregate, it is tempting to think that aggregation of part of the TDP-43 pool 
renders the antibody epitope inaccessible. In the FUSP525L line no alterations in TDP-43 
distribution were observed. 
 
In conclusion, this data shows that mutations in both FUS and TDP-43 have the capability to 
alter the nuclear levels of FUS, while nuclear TDP-43 levels are only altered by mutations in 
TDP-43 but not FUS. This makes sense, considering the lack of TDP-43 inclusion pathology 
in ALS caused by mutations in FUS (King et al., 2015). Vice versa, mislocalisation of FUS has 
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been observed in post-mortem tissue from patients with mutations in FUS, TDP-43, VCP or 
even sALS (Deng et al., 2010; Ikenaka et al., 2020; Tyzack et al., 2019).  
 
4.5.2 The somatic transcriptome is dysregulated in motor neurons carrying 
mutations in FUS and TDP-43 
 
Having established that our iPSC-derived motor neurons display ALS-like intracellular 
pathology, we then performed RNA-sequencing on the bulk cultures to investigate the 
transcriptomic alterations induced by the FUS and TDP-43 mutations. What we found was a 
largely distinct pattern of gene regulation between mutations (Fig. 15A). A set of 12 genes was 
commonly dysregulated between the FUSP525L and TDP-43M337V mutant lines. Nine of these 
were downregulated in both, including galectin-1 (LGALS1) and the endosome recycling 
protein RAB11FIP1, responsible for integrin recycling at distal axonal tips (Eva et al., 2010). 
Its downregulation might exert a deleterious effect on axonal outgrowth and synaptic 
maintenance. Only one gene, REG1A, was commonly upregulated. Its encoded protein is 
known to induce regeneration in several somatic tissues, and its expression in neurons improves 
neurite outgrowth (Ba et al., 2011). In our lines, the upregulation of REG1A is possibly a 
compensatory mechanism to counter the loss of other important neuronal functions. 
 Two genes were dysregulated in opposite directions: SLITRK4 and USP51. Both 
had increased expression in the FUSP525L line compared to control, but lower expression in the 
TDP-43M337V line. In addition, 5 genes were dysregulated across our two ALS lines and the 
FUS KO line. Among these was MAGEH1, that interacts with the p75 neurotrophic receptor 
(p75NTR) and has neuroprotective and anti-apoptotic effects in an in vitro model of 
frontotemporal dementia (Ehrlich et al., 2015). MAGEH1, similar to SLITRK4 and USP51, also 
showed upregulation in the FUSP525L line (as well as the FUS KO line), but downregulation in 
the TDP-43M337V motor neurons. Due to the comparison with the FUS KO line, this indicates 
that the dysregulation of MAGEH1 is driven by the loss of nuclear FUS, while SLITRK4 and 
USP51 are likely dysregulated due to gain-of-function of the mutant FUSP525L. 
 
To gain a better overview of dysregulated processes in our motor neurons, we then performed 
gene set enrichment analysis. We found many pathways significantly regulated in our lines, 
with a larger proportion of overlap between them as with individual dysregulated genes. Again, 
this analysis allowed us to pinpoint pathways that were unique to either the TDP-43M337V or 




In the TDP-43M337V motor neurons, we identified pathways pertaining to neural cell-cell 
adhesion enriched, as well as pathways related to GABA-receptor activity and transport of 
sodium and chloride ions. Downregulated were metabolic pathways, such as monosaccharide 
catabolic process and peptide metabolic process, as well as the GO-term mitochondrial matrix. 
The FUSP525L line showed unique upregulation of lysosomal pathways and microtubule bundle 
formation, while showing downregulation of splicing pathways and neurotrophic signalling. 
 Both lines showed common enrichment of transmembrane transport pathways of 
several classes of molecules, as well as potassium ion transport. The pathway 






Figure 15. Gene dysregulation in somas and axons of iPSC-derived motor neurons, induced by mutations 
in and knock-out of FUS and TDP-43. A. Differentially expressed genes in somas of FUSP525L, TDP-43M337V 
and FUS KO motor neurons, compared to isogenic control motor neurons. Green means upregulated in the mutant 
line, red means downregulated as compared to control B. Differentially expressed genes in axons of FUSP525L, 
TDP-43M337V and FUS KO motor neurons, compared to isogenic control motor neurons. Green means upregulated 
in the mutant line, red means downregulated as compared to control. C. Venn diagram cross-comparing the 
differentially expressed genes per line between axon and soma. 
 
As these pathways mentioned so far for the FUSP525L line were non-overlapping with the FUS 
KO line, it is implicated that these specific pathways are dysregulated due to gain-of-function 
of the mutant FUS. When investigating the dysregulated pathways in the FUS KO line, and its 
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overlap with the FUSP525L line it is interesting to note that here many pathways relating to 
synaptic functioning and signalling, synaptic membrane as well as vesicle transport are 
downregulated. This would suggest that while splicing defects are dysregulated in the FUSP525L 
line only, pathways implicated in synaptic dysfunction are mediated by loss of nuclear FUS. 
 
4.5.3 The axonal transcriptome is also dysregulated, but distinct from the 
events in somas 
 
Next, we turned to the transcriptomes from our motor axons. Similar to the mouse motor axons 
in Paper IV, we found that human motor axons contain approximately 5,000 unique transcripts 
with a strong enrichment for transcripts encoding proteins required for mitochondrial 
respiration, as well as ribosome subunits. An additional finding is the detection of the C9orf16 
transcript being strongly enriched in axons compared to somas. In Paper IV, we identified the 
mouse homolog 1110008P14Rik as being similarly enriched (Fig. 11B). Homologs exist only 
in vertebrates, and while its exact function is unknown, the protein is predicted to localise to 
microtubules. Even though C9orf16 appears to not be dysregulated in disease, it is still 
intriguing to find such a similar and strong axonal enrichment for this protein, indicating that 
it likely has an important function in axonal cytoskeletal formation and/or maintenance. 
 
Our ALS mutations induced dysregulation of a number of transcripts in axons (Fig. 15B).  Out 
of the 17 dysregulated genes in the FUSP525L line, two were KIF1A and KIF1B. These 
transcripts encode kinesin motor proteins, that mediate anterograde transport of various types 
of cargo, including synaptic vesicles (Okada et al., 1995). Their decreased expression in axons 
potentially disrupts axonal transport and vesicle release. 
 In the TDP-43M337V line, the axonal transcriptome hinted at metabolic 
dysregulation. A key component for the formation of the first complex in the mitochondrial 
respiratory chain, NDUFA10, was downregulated. In addition, WDR45 was downregulated. 
This protein is implicated in organellar autophagy, and reduced levels were shown to impair 
mitochondrial function, increase oxidative stress and indeed impair autophagic pathways 
(Seibler et al., 2018; Wan et al., 2019). Meanwhile, KIF1BP was upregulated in the TDP-
43M337V axons. This kinesin binding protein confers transport specificity to mitochondria, and 
its depletion causes the intracellular aggregation of mitochondria (Wozniak et al., 2005). 
Potentially, the neuron compensates for decreased mitochondrial function in axons by 




Finally, we observed that the transcriptome dysregulations due to mutations in FUS or TDP-
43 were largely distinct between axons and somas, with only a handful of genes being regulated 
in both compartments (Fig. 15C). In TDP-43M337V somas and axons, AKT1 was downregulated. 
As a known pro-survival factor, its downregulated may predispose these mutant neurons to be 
more prone to cellular stress. Other genes were regulated in different directions in the two 
cellular compartments. MORC3 was upregulated in somas in the TDP-43M337V line compared 
to control somas, but downregulated in the mutant axons. In the FUSP525L line, ATR, showed a 
similar pattern of expression. Both proteins are known to have important functions in the 
nucleus, with MORC able to generate ATP-dependent liquid-liquid phase separated droplets 
in the nucleus with a likely function to bring together DNA and DNA-binding proteins (Zhang 
et al., 2019), and ATR having a canonical role in DNA damage repair sensing and repair (Zou 
and Elledge, 2003). Their presence in axons suggests possible local non-canonical roles, 
however in the disease situation it appears that these proteins are recruited back to the soma, at 
the cost of their axonal expression. 
 
Taken together, our data shows that ALS-causative mutations in FUS and TDP-43 result in 
dysregulation of both the somatic and axonal transcriptomes. However, the pattern of gene 
regulation is largely unique to each mutation, implying that the initial upstream events 
occurring due to these mutations are non-overlapping. Using the FUS KO line, we were able 
to dissect out the gene regulation that is likely caused by loss of nuclear FUS, as well as which 
dysregulation is initiated by gain-of-function of FUSP525L. Our lines also showed distinct gene 
regulation in axons and somas, with both compartments presenting with sets of pathways or 
differentially expressed genes that in the future may present both central and peripheral targets 






5 FUTURE PERSPECTIVES 
 
In this thesis work, we first investigated the selective resistance to degeneration of oculomotor 
neurons compared to more vulnerable spinal motor neurons in both ALS and SMA. We 
employed both in vivo and in vitro approaches, by performing a transcriptomic analysis on 
different motor neuron pools in SMA mice, as well as generating oculomotor neurons from 
mouse stem cells. In doing so, we elucidated factors that can transfer resilience onto more 
vulnerable motor neurons, as exemplified most clearly by the protective effect of GDF15. This, 
combined with previous work of our lab showing the beneficial effects of expression of IGF-2 
and SYT13, provides novel therapeutic targets that can be applied across motor neuron 
diseases. One future direction is to assess synergistic effects of combinations of these factors, 
as they affect different aspects of neuronal physiology, providing strength to a combined 
therapeutic approach.  
 
An additional exciting avenue to pursue is the generation of human iPSC-derived oculomotor 
neurons. As we have shown in Paper V, mutations in ALS-causative genes affect the 
transcriptome and distribution of mutant proteins in iPSC-derived motor neurons. Being able 
to model spinal as well as oculomotor neurons will provide novel insights in how the resistant 
oculomotor neurons respond to varying mutations. This will go beyond identifying only 
pathways of degeneration in spinal motor neurons. In addition, potential differences in protein 
distribution, mislocalisation and aggregation in oculomotor neurons can be investigated. 
Oculomotor neurons possess multiple aspects rendering them more resistant, such as increased 
calcium-buffering potential, improved proteasome function, higher levels of pro-survival (Akt) 
signalling and upregulation of anti-apoptotic pathways in disease. Identifying which of these 
are most important in the face of mutations in various ALS-causative genes by modifying 
expression of components of these pathways will give important clues regarding how 
vulnerable neurons can be shielded best using endogenous signalling cascades in different 
disease contexts. 
 
The second part of this thesis concerns the selective vulnerability of the distal motor axon 
compared to the soma. As we showed in Paper I, neuromuscular defects in ALS start with pre-
synaptic dysfunction and denervation of the motor neuron at the NMJ. We then showed in 
Paper IV and Paper V that the presence of ALS-causative mutations in motor neurons causes 
transcriptome dysregulation. Together these papers highlight the cell-intrinsic processes 
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occurring in the motor neurons and particularly their axons, rendering stem cell-derived motor 
neurons and their isolated axons a novel and useful tool to study transcriptomic changes in the 
neuron itself. However, to recapitulate the in vivo environment more truthfully, as well as any 
pathological changes occurring to a neuromuscular synapse directly, the future development of 
this system should aim at generating functional in vitro NMJs. 
For one it will enable studying the details of whether and how local 
transcriptomic dysregulation in axons affects neuromuscular stability, maintenance and 
degeneration in ALS. Moreover, this system will push further maturation of the motor neurons, 
as they now synapse onto their physiological targets. It is expected that formation of a synapse 
will stabilise the developing motor axon transcriptome, as the requirements for growth and 
pathfinding disappear while the need for synaptic signalling and neurotransmitter release 
increase. Moreover, since dysfunction at the NMJ is one of the earliest phenotypes observed in 
ALS, this will provide novel ways for in vitro approaches to study motor neuron dysfunction, 
potentially without requiring external stressors or long periods of time to observe neuronal 
degeneration.  
The most exciting way to approach this would be to generate myofibres directly from 
iPSCs, much in the same way as the motor neurons. Using this approach, motor units could be 
created with ALS-causative mutations in both cell types, or only one of the two. This will allow 
dissection of disease-induced changes exerted by neurons and muscle onto each other, as well 
as the intricacies of their cell-to-cell communication. In conclusion, this system has the 
potential to reveal pathways of synaptic degeneration that can be targeted so as to preserve 
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